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Abstract 
After an episode of repetitive mild traumatic brain injury (rmTBI), many cellular and 
molecular cascades are initiated that result in the disruption of the structural and chemical 
integrity of the components in the brain, leading to the development of various cognitive 
deficits.  The goal of this thesis was to evaluate a mouse model of concussion in order to 
study the relationship between rmTBI, GSK3β and tau phosphorylation, and behavioural 
outcomes in a transgenic mouse line expressing solely human tau.  We found that there was 
increased phosphorylation of the two main regulatory sites on GSK3β, Tyr216 and Ser9, in 
the C57BL/6 mice.  When investigating the pathology and behaviour in the MAPT KI mice, 
there was positive silver staining, pathological tau staining (AT8), and increased Iba1 
staining compared to shams, with animals displaying cognitive deficits upon behavioural 
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Summary for Lay Audience 
Traumatic brain injuries (TBIs) are injuries that affect the structural integrity of the brain 
which, in turn, has a negative impact on brain functions and influences the behaviour of those 
affected.  The least severe form of TBIs, known as mild TBIs (mTBIs) includes concussions 
and sub-concussive closed head injuries.  When the exposure to mTBIs becomes repetitive, 
in other words repetitive mild traumatic brain injuries (rmTBI), there is an increased risk for 
the development of a neurodegenerative disease known as Chronic Traumatic 
Encephalopathy (CTE).  The main characteristic of this disease is the presence of abnormal 
tau protein aggregates in the brain.  One protein that has been implicated in the process of 
formation of these abnormal protein aggregates is called glycogen synthase kinase 3-beta 
(GSK3β).   
There is always the struggle of taking results from scientific studies involving animal models 
and then applying them to human beings.  However, technological advancements have 
allowed the development of genetic tools that have been applied to rodents in order to create 
ideal models with greater clinical relevance to human disease.  In this thesis I investigate a 
novel mouse model in which the entire mouse tau gene has been replaced with the human tau 
gene.  I use this mouse model to characterize the structural damage, at the cellular and 
molecular levels, that occur post-rmTBI, as well as the behavioural outcomes, in order to 
validate the use of this model in future research.   
 This study demonstrates that the novel mouse model is capable of developing the cellular 
and molecular injuries typical of rmTBIs.  The mice also demonstrate behavioural deficits 
that correlate with rmTBI injury, similar to that seen in humans.  Overall, this study supports 
the use of these mice for future rmTBI studies, as these mice are more clinically relevant and 
therefore more desirable models.  This study will hopefully serve as a stepping stone for 
future studies of rmTBI with a focus on further characterizing the pathology and developing 
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Chapter 1  
1 Introduction 
After an episode of repetitive mild traumatic brain injury (rmTBI), also referred to as 
concussions, many cascades are initiated that result in the deterioration of neurons, 
leading to degeneration within the brain and the development of cognitive deficits.  
Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease that develops 
from repetitive impacts sustained to the head causing concussions (Lucke-Wold et al., 
2014).  This has been observed in both athletes, those in contact sports, and military 
personnel (Lucke-Wold et al., 2014).  It is characterized as a tauopathy as one of the 
major defining features of the disease involves tau, a microtubule-associated protein.  
Abnormally phosphorylated tau within neurons begins to form aggregates, fibrils, and 
tangles, which disrupts normal cell functions such as microtubule assembly and the 
ability to maintain stable structure within the cell (Kolarova et al, 2012).  Abnormal 
phosphorylation of tau not only causes pathology within neurons, but it also results in 
cognitive impairments due to the degeneration within the brain itself (Kolarova et al, 
2012).  This leads to progressive cognitive impairments/dementia such as memory 
deficits, depression, and increased anxiety/anxiety related behaviours (Luo et al., 2014), 
observed in CTE.  I sought to develop a clinically relevant mouse model of 
concussion/rmTBI to study the pathophysiological mechanisms that lead to CTE.  One 
mechanism that has been put forward to explain the development of CTE following 
rmTBI focuses on the tau kinase, glycogen synthase kinase 3-beta (GSK3β) (Dash et al., 
2011; Moszczynski et al., 2018).  It has been proposed that GSK3β is responsible for the 
abnormal phosphorylation of tau in tauopathies, such as CTE (Hooper, Killick, and 
Lovestone, 2008).  This abnormal phosphorylation of tau is what leads to the pathological 
formation of aggregates/fibrils/tangles leading to neuronal death (Polydoro et al., 2009). 
A model of concussion needs to mimic the tell-tale features of human injury including the 
cellular pathologies, molecular pathologies, and behavioural outcomes post-injury.  The 
accumulation of all of these features is what ultimately leads to the eventual development 
of CTE.  It is the goal of this thesis to develop and evaluate a mouse model of concussion 
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in order to study the relationship between rmTBI, GSK3β activity, tau phosphorylation 
and the development of cognitive deficits in a transgenic mouse line expressing solely 
human tau. 
1.1 Concussion 
Traumatic Brain Injuries (aka Primary Injuries)   
Traumatic brain injuries (TBIs) are a devastating set of injuries that affect the structural 
and chemical integrity of the brain which, in turn, influences the behaviour of those 
affected (Bramlett & Dietrich, 2015; Kokiko-Cochran et al., 2018; Shultz et al., 2020).  
When severe, TBIs affect the rest of the central nervous system and cause permanent 
damage to the brain or even death (Ling et al., 2015).  TBIs have recently become of 
more interest due to the increasing awareness of the general public, as they are a huge 
health concern (Yap et al., 2017).  The complications that arise, post-TBI, create a ripple 
effect in the health care system, the economy, and cause strain in those closest to the 
individuals who are injured (Siebold et al., 2018).  Anyone can be affected by a TBI, 
however, some individuals are more at risk than others.  Individuals who partake in 
contact sports, are enrolled in the military, or have careers that increase the probability of 
injury, are all examples of individuals that are at a higher risk of incurring a TBI (McKee 
et al., 2009).    
TBIs may be classed based on their severity as mild, moderate or severe.  Several clinical 
assessment tools have been developed and used in order to assess the severity of a 
sustained TBI including various imaging techniques, timing and/or presence of loss of 
consciousness, presence and/or absence of amnesia, and finally the Glasgow Coma Scale 
(Siebold et al., 2018).  The least severe classification of TBIs, known as mild TBI 
(mTBI), includes injuries referred to as concussions and sub-concussive injuries, which 
involve acceleration, deceleration and rotational mechanical forces transmitted to the 
brain upon impact resulting in shearing of brain tissues (Montenigro et al., 2017).  
Concussions and sub-concussive injuries are typically closed head injuries which do not 
involve penetrating forces (Tagge et al., 2018).  Specifically, concussions can be defined 
as any impact that directly or indirectly involves the head producing a number of 
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symptoms which can recover over a variable length of time, depending on the 
individuals’ circumstance (Montenigro et al., 2017).  However, sub-concussions can be 
defined similarly to that of concussions, with the exception that sub-concussions fail to 
produce visible symptoms (Bailes et al., 2013; Erlanger, 2015; Montenigro et al., 2017). 
When repetitive, the pathological sequelae of rmTBIs can accumulate and activate 
secondary injury cascades and potentially the development of neurological disease 
(Bailes et al., 2013).  
There are many external factors that influence the severity of an mTBI.  It has been 
proposed that acceleration and deceleration forces play an important role in the outcome 
of the severity of injury (Ling et al., 2015).   These forces can act on the brain either in a 
linear or non-linear/rotational manner, depending on the mechanism or method of 
delivery for the injury (Ling et al., 2015).  The result is the brain, consisting of all of the 
neurons, glia cells, and other components, being mechanically disarrayed (Ling et al., 
2015).  The location of the insult, the magnitude of the force behind the injury, the 
amount of surface area affected, and the amount of freedom of the head to move during 
impact are also factors to consider (Bolton-Hall et al., 2019). 
There are instances in which individuals experience more than one mTBI in a given 
period of time, referred to as repetitive/repeated mild traumatic brain injury (Donovan et 
al., 2014).  Repetitive mTBI can potentially lead to the development of second-impact 
syndrome (SIS) (Cobb & Battin, 2004) in which there can be serious consequences 
including death.  It has been shown that there is a window of time in which the brain is 
more vulnerable to a second potential impact after the initial injury (Laurer et al., 2001; 
Longhi et al., 2005) contributing to the development of SIS.  With each injury, the 
pathological cascades and behavioural symptoms become additive (Cobb & Battin, 
2004).     
TBI is often described as having two components: a primary injury and a secondary 
injury.  The primary injury/TBI involves the physical disruption of the brain and includes 
various mechanical disruptions such as the shearing and stretching of axons (Cernak et 
al., 2004).  However, not all primary injuries/TBIs are the same and this makes treatment 
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difficult as the nature of these injuries are very heterogenous (Siebold et al., 2018; 
Washington et al., 2012).  The primary injury/TBI initiates many secondary injury 
cascades, such as, diffuse axonal injury, apoptosis, and ionic disturbances (Cernak et al., 
2004).  The intensity and duration of these secondary injury cascades depends ultimately 
on the severity of the initial injury.  
Secondary Injuries  
Secondary injuries are considered to be any and all pathological cascades that occur after 
the initial insult to the brain (Cernak et al., 2004).  Secondary injuries can roughly be 
sorted into two major categories: secondary cellular injuries and secondary molecular 
injuries, which both lead to the development of behavioural deficits (Krishnamurthy K & 
Laskowitz DT, 2016; Washington et al., 2012).  It is worthy to note that certain cases of 
cellular injury, such as immediate cell death or direct damage to brain tissues, can be 
considered by some to be primary injuries as they are a result originating directly from 
the impact (Abdul-Muneer et al., 2015).  Behavioural outcomes, on the other hand, are a 
result of the additive effects of both the secondary cellular and molecular injuries 
produced from the initial trauma (T. Chen et al., 2011; Davis, 2000).   
Secondary Cellular Injuries  
Secondary cellular injuries result in mechanical damage to the various structures within 
the brain (J. R. Hay et al., 2015), as well as damage to cells and/or organelles within the 
central nervous system (Haber et al., 2017; Mbye et al., 2008).  There have been several 
studies that have investigated the effect of TBIs on the integrity of the blood brain barrier 
(BBB) post-injury (J. R. Hay et al., 2015; Tomkins et al., 2011; Weissberg et al., 2014).  
Interestingly, one study investigating the effects of concussive and sub-concussive 
impacts on football players found that there was increased BBB permeability in both the 
gray and white matter areas in approximately 40% of the players that were analyzed 
(Weissberg et al., 2014).  The authors postulated that this could be influenced by repeated 
exposures to sub-concussive events that go unnoticed at the time of the injury, or due to 
neglected or unreported concussive events (Weissberg et al., 2014).  The vasculature 
within the brain is also at risk post-injury, as mTBIs cause damage to the blood vessels as 
5 
 
a whole and microstructural damage to the vascular cells which decreases and alters 
blood flow and brain function (Jullienne et al., 2016; Monson et al., 2019).  Depending 
on the severity of the TBI, the location of the injury and the method of delivery, a 
beneficial or a harmful/prolonged inflammatory response may develop (Burda et al., 
2016).  With the integrity of the BBB being compromised post-TBI, there is the 
possibility of the inflammatory response to be sustained by incoming neutrophils, 
monocytes, and lymphocytes (Ziebell & Morganti-Kossmann, 2010).   
The mechanical forces of TBIs also cause stretching, shearing and/or tearing of the 
neurons and axons of neurons within the brain which, in turn, results in diffuse axonal 
injuries (DAI) throughout the white matter (Yap et al., 2017).  DAI is considered to be a 
hallmark of TBIs and is of great concern as it results in the disruption of axonal transport, 
production of retraction bulbs, and in more severe cases, axonal loss and degeneration 
(Haber et al., 2017).  It was discovered that even under very mild axonal stretch 
conditions there was increased growth cone collapse and smaller growth cones within the 
tips of regenerative sprouts in developing axons (Yap et al., 2017).  Another study, 
investigating the relationship between diffusion tensor imaging (DTI) and DAI in a 
Closed-Head Impact Model of Engineered Rotational Acceleration (CHIMERA) mouse 
model of TBI, discovered that there were DTI abnormalities, post-injury, indicating 
damage to several white matter tracts such as the optic tract and the corpus callosum 
(Haber et al., 2017).  Silver staining of sections from injured brains was used to confirm 
the findings of the DTI results.  Unfortunately, when cellular damage occurs it can result 
in various components within the cell to be damaged as well.  Organelles, in particular 
the mitochondria which are essential to neuronal function, are also subject to injury upon 
TBI (Mbye et al., 2008).  Upon injury, many cascades are thrown into disarray (such as 
Ca2+ homeostasis, activation of calpains and caspases, increases in oxidative stress), 
which results in mitochondrial dysregulation, and ultimately neuronal death (G. Cheng et 
al., 2012).  All of these examples of cellular injury due to TBIs, and many more, are 




Secondary Molecular Injuries    
There are many molecular cascades and pathways that are activated post-TBI that are 
classified as secondary molecular injuries such as the generation of reactive oxygen 
species (ROS)/reactive nitrogen species (RNS), proapoptotic signals, activation of 
various enzymes, and production of inflammatory signals (Bramlett & Dietrich, 2015), 
and many more.  TBIs create an environment in which the balance of antioxidants and the 
generation of ROS/RNS becomes altered, favouring the production of the latter, thus 
resulting in oxidative stress (Abdul-Muneer et al., 2015).  The production of these free 
radicals, in this case ROS/RNS, poses a serious threat to the maintenance of cellular 
homeostasis as these radicals are capable of interacting and reacting with any cellular 
components, therefore compromising cellular function (Tyurin et al., 2000).  Oxidative 
stresses play a role in a number of other secondary injury processes, both cellular and 
molecular.  Oxidative stress has been implicated in the increased permeability of the BBB 
and brain vasculature, further facilitating inflammation by directly/indirectly initiating the 
production of various neuroinflammatory signals, and damage to proteins, DNA, and 
mitochondrial function (Abdul-Muneer et al., 2015; Ansari et al., 2008).  
Apoptosis, a form of programmed cell death, can be an early or delayed post-injury 
response that ultimately results in neuronal death (Uzan et al., 2006; X. Zhang et al., 
2004).  The initiation of apoptosis can occur via a number of different pathways, all of 
which able to interact with one another (X. Zhang et al., 2004) to result in the completion 
of apoptosis.  One method of apoptosis induction is through the activation of caspases, a 
family of proteases, initiated through intrinsic and/or extrinsic routes.  Intrinsic activation 
signals consist of various stress signals from mitochondria contained within the cell, 
however, extrinsic signals consist of a number of signals binding to their respective 
receptors (Uzan et al., 2006).  Both intrinsic and extrinsic pathways initiate the 
proteolytic cleavage of members of the caspase family which allow the enzymes to be 
able to interact with their substrates, resulting in DNA fragmentation, cytoskeletal 
disintegration, and ultimately apoptosis (X. Zhang et al., 2004).  Another method of 
regulation for the process of apoptosis is through the balance of members of the B-cell 
lymphoma-2 (Bcl-2) family.  The Bcl-2 family consists of both pro- and anti- cell death 
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signals, and the balance of these signals influence whether or not apoptosis will occur 
(Wong et al., 2005). Events, such as TBIs, can tip the scales in favour of apoptosis 
through the activation/imbalance of any of these pathways resulting not only in neuronal 
death, but the death of various glial cells as well (X. Zhang et al., 2004).                    
Once a TBI has occurred, there are many molecular pathways that are involved in the 
inflammatory process that are activated and are able to influence various cellular changes 
that occur throughout the inflammatory response (Ghirnikar et al., 1998).  Some of these 
pathways include the release of several mediators such as prostaglandins, free radicals 
(ROS/RNS), and cytokines which facilitate the expression of chemokines (Ghirnikar et 
al., 1998).  The production and levels of cytokines and chemokines play a role in the 
neuropathological outcome after TBIs.  There is controversy surrounding the therapeutic 
value of inflammation post-injury, due to the fact that inflammation can benefit the 
central nervous system by clearing out damaged cells and debris, while a pro-longed 
inflammatory response can be detrimental (Morganti-Kossmann et al., 2001).  In 
particular, cytokines involved in the inflammatory process can be divided into two 
subgroups, one being cytokines with pro-inflammatory properties and the other being 
cytokines with anti-inflammatory properties (T. Chen et al., 2011).  One study 
investigating the effects of administration of salvianolic acid B (SalB) on TBI found that 
SalB blocked the activities of pro-inflammatory cytokines, thus preventing the infiltration 
of incoming inflammatory cells while increasing the expression of anti-inflammatory 
cytokines (T. Chen et al., 2011).  The treatment with SalB resulted in various 
improvements post-TBI in the form of decreased lesion volumes, brain edema, and 
behavioural deficits with decreases in motor functional and spatial learning/memory 
impairments (T. Chen et al., 2011).          
Behavioural Outcomes  
There are many cognitive, behavioural, and emotional conditions that arise post-
TBI/TBIs due to the accumulated actions of secondary cellular and molecular injury 
processes (Davis, 2000; Washington et al., 2012).  The intensity, the number, and the 
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nature of the TBIs can influence the prevalence of these conditions post-injury 
(Washington et al., 2012).   
The most common behavioural outcome occurring after TBIs is the development of 
depression, with a higher percentage of individuals developing some level of depression 
post-injury compared to anxiety (Leong Bin Abdullah et al., 2018; Mauri et al., 2014).  
One study investigating the prevalence of Axis I and II disorders (mental 
health/substance use disorders versus personality/mood disorders), post-TBI, discovered 
that the development of major depression was present at both the acute and chronic time 
points of the study, all the way up to the 30 year follow up checkpoint (Koponen et al., 
2002).  The onset of depression post-TBI can be attributed to the damage from the initial 
injury itself, various secondary injury pathways (example: decreased glucose 
metabolism), and external lifestyle factors (Fann et al., 2009).  There is a possibility that 
individuals who experience TBIs, and develop depression, can also develop anxiety as 
well, on top of the depression, making treatment even more difficult (Barker-Collo et al., 
2018). 
Anxiety disorders are another common behavioural outcome after TBIs.  There is an 
increased risk for the development of several anxiety disorders post-injury including 
generalized anxiety disorder (GAD), obsessive compulsive disorder (OCD), panic 
disorder, and others (Hiott & Labbate, 2002).  In one study, the authors sought to 
investigate anxiety/anxiety-like behaviours in a rodent mild blast TBI model and aimed to 
correlate the behavioural outcomes to possible changes at the genetic level (Blaze et al., 
2020).  In this study there were significant increases in anxiety/anxiety-like behaviour at 
the acute time points studied and, while not statistically significant, there was a trend 
towards increased anxiety at chronic time points.  This study also showed that there were 
significant changes in gene expression in the amygdala post-TBI at chronic time points 
by transcriptomic analyses (Blaze et al., 2020).  Other reports have indicated changes in 
the structural features of the amygdala as well as differences in various molecular 
processes, such as levels of mRNA and protein expression (Almeida-Suhett et al., 2014; 
Tate et al., 2016).   
9 
 
The relationship between TBIs and posttraumatic stress disorder (PTSD) is both 
controversial and complex (Y.-F. Chen & Zhao, 2019).  Scientists have proposed that in 
some circumstances TBIs, in particular mTBIs/rmTBIs, can be an important risk factor 
for the development of this anxiety disorder (Hoge et al., 2008).  This could be in large 
part due to the fact that individuals who suffer mTBIs/rmTBIs in a traumatic scenario are 
able to remember the traumatic event due to lack of loss of consciousness and are more 
likely to develop PTSD  (Gil et al., 2005).  Situations that typically give rise to PTSD 
tend to also involve the potential for incurring TBIs, such as active military personnel or 
abuse victims (Y.-F. Chen & Zhao, 2019).  Both TBIs and PTSD lead to the development 
of several undesirable and harmful behavioural traits including depression, violence, 
substance abuse, and suicidal tendencies (Y.-F. Chen & Zhao, 2019). 
Cognition, memory, and learning processes are all negatively affected by TBIs.  There is 
decreased spatial information processing, and decreased learning and memory 
processing, all of which are dependent on the hippocampus (Pierce et al., 1998; Rola et 
al., 2006).  There are many underlying pathological pathways that are initiated, post-TBI, 
that could play a role in the cognitive/learning/memory deficits observed.  In particular, 
one study looking into the effects of TBIs on neurogenesis in the hippocampus found 
evidence of cell loss/death, changes in cell fates, and evidence of persisting inflammation 
(Rola et al., 2006).  Another study revealed that TBI increases the production of ROS 
(corresponding to oxidative stress) and decreases antioxidant and synaptic protein levels 
(Ansari et al., 2008), most likely contributing to cellular dysfunction/cell death in the 
hippocampus and behavioural deficits. Overall, the nature of TBIs is quite heterogeneous 
as is the patient population therefore making behavioural deficits difficult to predict.         
Outcomes Post-Concussion 
Ultimately there are four possible outcomes after an episode(s) of TBI. First, a concussed 
individual can have symptoms acutely that then resolve within days or weeks (Alexander, 
1995).  Second, a concussed individual may develop post-concussive syndrome (PCS), in 
which the symptoms take longer, months or even years, to resolve (Maroon et al., 2012).  
PCS is a very complex phenomenon in which the composition of symptoms can vary 
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within the same individual over time (Maroon et al., 2012).  Third, an unfortunate 
subgroup of concussed individuals may go on to develop a neurodegenerative disease 
known as Chronic Traumatic Encephalopathy (CTE) (McKee et al., 2013).  Concussions 
have been shown to be a risk factor for the development of CTE in several studies 
(McKee et al., 2009, 2013; Roberts et al., 1990).  There is also a possibility to further 
develop other neurodegenerative characteristics or diseases alongside CTE such as CTE 
with Alzheimer’s Disease (AD) (Turner et al., 2016; Yuan & Wang, 2018), CTE with 
Amyotrophic Lateral Sclerosis (ALS) (Moszczynski et al., 2018; Walt et al., 2018), and 
CTE with other pathological protein deposits, such as transactive response DNA-binding 
protein of 43 kDa (TDP-43) (Heyburn et al., 2019; McKee et al., 2010).  The fourth 
possible outcome after TBI is death, either from complications post-injury, SIS (Cobb & 
Battin, 2004), and eventual death from the development of CTE.   
1.2 Chronic Traumatic Encephalopathy  
History of Chronic Traumatic Encephalopathy  
In 1928, an initial description of what is now known to be CTE was first described by Dr. 
Martland as he analyzed the brain pathology and behaviours of boxers known to be 
“punch drunk” who had developed both mild and severe symptoms (Martland, 1928).  He 
proposed that the development of the “punch drunk” syndrome was the result of multiple 
injuries to the head (Martland, 1928).  In 1934, Dr. Parker expanded upon the work of Dr. 
Martland and referred to the syndrome as “traumatic encephalopathy” (Parker, 1934).  
Dr. Parker confirmed that repeated injuries to the head sustained during the sporting 
careers of boxers leads to the development of numerous symptoms, which he referred to 
as a ‘medley’ of symptoms (Parker, 1934).  Later, in 1937, another scientist named 
Millspaugh observed similar symptoms and behaviours as Martland, mostly in boxers, 
and used a different term, “dementia pugilistica” (Baugh et al., 2012).  Many other 
scientists and researchers over time have looked into this phenomenon and many names 
were put forward (Stein et al., 2014).  It was during the 1940s that the term “Chronic 
Traumatic Encephalopathy” (CTE) was coined, and it is now widely used and accepted 
(Montenigro et al., 2015).  Since then, the study of CTE has advanced and the natural 
progression of CTE has been characterized (McKee et al., 2013).       
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Risk Factors for Chronic Traumatic Encephalopathy  
Both environmental and genetic risk factors, and the interaction between these risk 
factors, play a role in the development of CTE (Gavett et al., 2010). The most obvious 
environmental risk factor for the development of CTE is the exposure to rmTBIs  (Gavett 
et al., 2010, 2011; McKee et al., 2009).  As mentioned previously, individuals who 
participate in contact sports, are enrolled in the military, suffer from domestic abuse, or 
have any instance where exposure to repeated concussive or sub-concussive impacts is 
increased, have a greater risk of developing CTE (Baugh et al., 2012).  Individuals who 
experience frequent falls, vehicular accidents, or have epilepsy are also populations at 
risk for the development of CTE (Gavett et al., 2010).     
Genetic background also plays a role in the recovery from TBI and may explain some of 
the variability seen in the recovery process (McAllister, 2010).  Candidate genes and their 
respective alleles, as well as various epigenetic factors acting on these genes, can act 
alone or interact and therefore influence the outcome(s) post-injury (McAllister, 2010).  
There are several known genetic risk factors associated with a poorer outcome post-injury 
(J. Hay et al., 2016).  Individuals with the APOE Ɛ4 allele and/or the longer microsatellite 
polymorphism repeat located in the promoter in the neprilysin gene (NEP) are subject to 
a greater risk for the development of amyloid beta (Aβ) plaques, and neurological 
impairment post-TBI (J. Hay et al., 2016).  Polymorphisms in TP53, angiotensin-
converting enzyme (ACE), and calcium channel subunit gene (CACNA1A), are also 
associated with a poorer outcome post-TBI (McAllister, 2010).  The involvement of 
many genes in the molecular cascades activated by secondary injury mechanisms is 
believed to explain why so many genes may influence the level of risk for developing 
neurodegenerative disease following TBI (McAllister, 2010).                   
Progression of Chronic Traumatic Encephalopathy  
In 2013, McKee and colleagues set out to characterize the progression and spectrum of 
the neuropathological changes associated with CTE (McKee et al., 2013).  The results 
demonstrate that the brains of concussed subjects analyzed could be sorted into one of 
four stages with a distinct pattern of pathological protein and other microscopic changes.  
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Stage I is the mildest of the stages of CTE progression.  Brains classified as stage I CTE 
show little ventricular enlargement with focal perivascular pathological tau protein 
located in the depths of cortical sulci.  Brains classified as stage II (mild CTE) show 
ventricular enlargement, increases in pathological tau protein that penetrate the 
superficial layers of the cortex, and small amounts of pathological tau in areas such as the 
hippocampus, entorhinal cortex, and thalamus.  Brains classified as stage III (moderate 
CTE) show areas of brain atrophy, axonal loss in subcortical white matter, and increased 
pathological tau spread throughout the cortices, hippocampus, entorhinal cortex and 
amygdala.  The final stage of CTE, Stage IV, is the most severe stage.  This stage 
includes significant brain atrophy in several brain areas, decreased overall brain weight, 
significant ventricular enlargement, significant neuronal death and widely distributed 
pathological tau protein.  The complete characterization of the progression of CTE can be 
found in the paper of McKee et al. (2013), with more information found in the work of 
Stein and fellow colleagues (Stein et al., 2014).  Overall, the pathology of CTE increases 
as the stages progress from Stage I (very mild) to Stage IV (severe).  Although CTE can 
be present alongside other neurodegenerative diseases and have other pathological 
proteins/processes present, CTE is characterized as a tauopathy due to the fact that the 
main pathological hallmark is the deposition of pathological phopho-tau aggregates.  
1.3 Tau 
The Microtubule-Associated Protein Tau (MAPT) 
Tau proteins are members of the microtubule-associated protein (MAP) family (Binder et 
al., 1985; Brandt et al., 2005).  The main function of tau is to help stabilize, bind, and 
regulate microtubule dynamics in the axons of neurons (Arendt et al., 2016). However, 
there are many other functions of tau within cells, such as interacting with other cellular 
components, like the mitochondria and the plasma membrane, and potentially playing a 
role in various signaling processes (Kolarova et al., 2012).        
Tau proteins are expressed both in the peripheral nervous system and in the central 
nervous system (Arendt et al., 2016), with trace amounts of tau mRNA in several 
peripheral tissues (Buée et al., 2000). Within the central nervous system, tau proteins are 
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expressed predominantly in neurons (Kolarova et al., 2012). Tau can also be found both 
within oligodendrocytes (Arendt et al., 2016) as well as in astrocytes (Arena et al., 2020).  
In healthy neuronal cells tau is localized in the axonal compartment, where it’s primary 
function is to interact with microtubules (M Goedert & Jakes, 1990). With regard to 
human tau proteins, the single gene responsible for the production of all of the tau family 
members is located on chromosome 17, position 17q21 (Kolarova et al., 2012). There are 
a total of 16 exons contained within this gene, of those, 11 are involved in alternative 
splicing (Brandt et al., 2005; M Goedert et al., 1988).  Three of the exons are not 
transcribed in the brain at all, specifically, exons 4A, 6 and 8 (Park et al., 2016).  The 
alternative splicing generates six unique tau isoforms that differ with respect to the 
number of binding domain repeats at the C-terminal end and either the presence or 
absence of two N-terminal amino acid inserts (Arendt et al., 2016).  Specifically, the 
regions subjected to alternative splicing, that create the unique isoforms in the brain, are 
encoded by exons 2, 3, and 10 (M Goedert et al., 1989; Park et al., 2016).  Exons 2 and 3 
can be spliced so that neither of them, exon 2, or both exon 2 and 3 can be included in the 
structure of the isoforms, resulting in a 0N, 1N, or 2N isoform (Arendt et al., 2016; Park 
et al., 2016).  The alternative splicing of exon 10 results in either the exclusion of this 
exon, 3R tau isoforms, or the inclusion of this exon, resulting in 4R tau isoforms (Brandt 
et al., 2005).  As a result, of these combined alternative splicing’s, six tau isoforms are 
generated and are referred to as 0N3R, 1N3R, 2N3R, 0N4R, 1N4R, and 2N4R (Kolarova 
et al., 2012).  It is important to note that the previously described tau isoforms apply to 
the tau isoforms located in the central nervous system, as the peripheral nervous system 
has an additional tau isoform, referred to as “big tau” (Brandt et al., 2005; M Goedert et 
al., 1992).  
The Structure and Developmental Expression of Tau 
Tau is a natively unfolded protein with little secondary structure (Arendt et al., 2016; 
Kolarova et al., 2012).  However, the differences between the various tau isoforms dictate 
the functional outcome of each of the proteins, and therefore influence their interactions 
with microtubules, especially during development (Kolarova et al., 2012).  During 
development, the tau isoforms are differentially regulated and expressed (Kosik et al., 
14 
 
1989). In the fetal brain, only 3R isoforms are expressed, whereas in the adult human 
brain, both 3R and 4R isoforms are expressed equally at a ratio of approximately 1:1 (M 
Goedert & Jakes, 1990; Hanes et al., 2009).  It has been demonstrated that the 4R isoform 
is capable of binding microtubules more efficiently than their 3R counterparts (M 
Goedert & Jakes, 1990). This seems to reflect the change in plasticity within the brain as 
it ages, as 3R tau’s weak binding to microtubules will allow for greater neuroplasticity 
during neuronal development while the strong microtubule binding of 4R tau will 
decrease neuroplasticity by enhancing microtubule stability (Arendt et al., 2016).  
Post-Translational Modifications of Tau 
Tau proteins are not only regulated by alternative splicing throughout development, but 
also by various post-translational modifications. These modifications influence tau’s 
ability to bind and stabilize microtubules (Sergeant et al., 2005). Tau can be modified 
through the process of O-glycosylation, glycation, ubiquitination, SUMOylation, 
nitration, methylation, acetylation, truncation, and more, all of which affect tau’s ability 
to function and potentially become pathogenic (Arendt et al., 2016).  The most studied 
and well-known modification of tau is its phosphorylation at regulatory sites. Tau itself is 
considered a phosphoprotein (Trinczek et al., 1995), as there are approximately 80 sites 
available for potential phosphorylation on the longest tau isoform (Sergeant et al., 2005). 
Pathological phosphorylation of tau leads to the deposition of tau aggregates and disease.  
Tau and Tauopathies 
Tauopathies are a group of heterogeneous neurodegenerative diseases characterized by 
filamentous tau aggregates consisting of hyperphosphorylated tau proteins (Kovacs, 
2018; V. M.-Y. Lee et al., 2001).  Tauopathies may be classified based on the unique 
composition of their tau aggregates (Sergeant et al., 2005).  Tauopathies can be further 
subdivided into either sporadic or familial tauopathies, in which sporadic tauopathies 
arise spontaneously and familial tauopathies arise due to inherited mutations (Arendt et 
al., 2016). Tauopathies may also be classified as either primary or secondary, depending 
on how significant the tau pathology is, and the severity of other coincident pathological 
features (Kovacs, 2018).  Each tauopathy is unique, as the distribution of tau, isoforms 
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present, isoform ratio balance, and presence/absence of other pathological features is 
specific to each respective disease (Arendt et al., 2016; Sergeant et al., 2005).   
Familial Tauopathies 
Over 30 genetic mutations have been implicated in the development of familial 
tauopathies (Engel et al., 2006; Michel Goedert & Jakes, 2005).  Missense, deletion, and 
silent mutations involving the exons of the tau gene can influence the outcomes of 
alternative splicing, as can various mutations in the intron sequences (Niblock & Gallo, 
2012).  When the regulation of alternative splicing becomes altered, the production of 3R 
and 4R tau isoforms becomes unbalanced, affecting the normal physiological isoform 
ratio (Niblock & Gallo, 2012).  Besides mutations to the introns, exons, or both the 
introns and exons, there can also be genetic alterations involving the entire sequence of 
the tau gene.  The genetic inversion of the DNA region containing the tau MAPT gene 
results in the production of two haplotypes, H1 and H2, with the H1 haplotype having 
several sub-haplotypes, some of which are associated with the development of 
tauopathies (Niblock & Gallo, 2012; Sánchez-Juan et al., 2019). 
Sporadic Tauopathies  
Typically, sporadic tauopathies originate in a vulnerable area of the brain and 
subsequently the pathological tau aggregates spread throughout the rest of the brain 
through the neuronal pathways connecting them (Sergeant et al., 2005).  When the ratios 
of 3R:4R isoforms become unbalanced or the modifications influencing tau’s activity 
become dysregulated, or external triggers, such as substance abuse or brain injuries, 
occur, sporadic tauopathies may emerge (Arendt et al., 2016; Irwin et al., 2013).    
Tau as a Prion Protein 
A proposed mechanism for the propagation of pathological tau throughout the brain is via 
a prion-like mechanism.  This mechanism involves the corruption of native proteins into 
pathological proteins and aggregates using a template-dependent manner from 
pathological tau (Kumar & Udgaonkar, 2018).  The forms of pathological tau, in this 
case, are referred to as “strains” and each strain has a distinct fibrillar structure (Sanders 
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et al., 2014).  The characteristics of each strain determines the characteristics of the 
disease that manifests.  These strains of pathological tau are stable and are able to 
propagate from cell-to-cell through synapses (Mudher et al., 2017).  This could explain 
how tau is able to spread from vulnerable brain regions to connecting brain areas.  
Imbalance of Post-translational Phosphorylation of Tau  
There have been several studies that have investigated various post-translational 
modifications of tau and how these modifications play into aggregate formation and/or 
disease progression (Arendt et al., 2016; Morris et al., 2015).  Of particular interest is the 
post-translational phosphorylation of tau. As mentioned above, tau is known to be a 
phosphoprotein in which the level of phosphorylation naturally influences and regulates 
tau function (Buée et al., 2000; Trinczek et al., 1995).  However, diseases may arise when 
tau becomes pathologically hyperphosphorylated (Kolarova et al., 2012).  It has been 
proposed that an imbalance in the activities and regulations of protein kinases and 
phosphatases results in the hyperphosphorylation of tau, either through an increase in 
kinase activity or a decrease in phosphatase activity (Buée et al., 2000).  
1.4 Glycogen Synthase Kinase 3  
Overview 
Glycogen synthase kinase 3 (GSK3) is a ubiquitously expressed proline-directed 
serine/threonine kinase that is constitutively active (Beurel et al., 2015; Hooper et al., 
2008).  It consists of two important functional domains: a primed substrate binding 
domain and a kinase domain (Beurel et al., 2015).  Initially discovered in the 1970s for its 
role in the phosphorylation and regulation of glycogen synthase, GSK3 has since been 
implicated in many other cellular and signaling pathways (Cohen & Goedert, 2004).  
GSK3 is involved in glycogen metabolism, gene transcription, apoptosis, inflammation, 
and microtubule stability, just to name a few cellular processes (Cohen & Goedert, 2004; 
Hooper et al., 2008). There are two unique aspects to GSK3 activity: 1) GSK3 is 
constitutively active and 2) GSK3 may phosphorylate both primed and un-primed 
substrates (Beurel et al., 2015; Hooper et al., 2008).  The “priming” of the substrates 
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involves the phosphorylation of a site approximately 4 residues to the C-terminal side of 
the target site, which allows the substrate to bind to the GSK3 primed substrate binding 
domain (Beurel et al., 2015).  GSK3 is regulated by a number of kinases and 
phosphatases and the breakdown of these regulations has been implicated in the increased 
risk of disease (Hooper et al., 2008).       
Regulation of Glycogen Synthase Kinase 3 
There are many post-translational regulatory mechanisms that keep the activity of GSK3 
in check.  Post-translational modifications, substrate priming, association with protein 
complexes, and regulation of expression and degradation are all mechanisms that are 
capable of regulating GSK3 (Beurel et al., 2015).  Post-translational acetylation of GSK3 
can influence whether GSK3 activity is increased or decreased.  When acetylated, the 
activity of GSK3 proteins is suppressed, however, when the proteins become 
deacetylated, the levels of activity increase (Monteserin-Garcia et al., 2013).  Much more 
work needs to be done in order to tease apart the effect that other non-phosphorylation 
dependent post-translation modifications have on GSK3 activity (Beurel et al., 2015).  
Substrate priming is another method of controlling the levels of activity of GSK3.  This 
method is more complex than mere post-translational modifications, as not only does the 
substrate have to be pre-phosphorylated at the correct site, thus being primed for GSK3 
proteins, but activated GSK3 proteins must be in the vicinity of the primed substrate 
(Beurel et al., 2015).  The priming of the substrate requires that other signaling pathways 
be active and phosphorylating the desired substrate at approximately 4 residues C-
terminal to the target motif (Beurel et al., 2015).  One way to directly influence the 
activities of GSK3 phosphorylation is to incorporate GSK3 into a number of different 
protein complexes, depending on the desired substrates and outcomes.  For example, one 
of the most well known protein complexes involving GSK3 is the destruction complex of 
the Wnt signalling pathway (Kim et al., 2009).  GSK3 forms a destruction complex with 
various other proteins in order to phosphorylate and target β-catenin for degradation (Kim 
et al., 2009).  In addition to these methods of regulating GSK3 activity, GSK can also be 
regulated by its cellular sequestration to the mitochondria, the nucleus or the cytosol, of 
the cell (Beurel et al., 2015).  In the next section I will discuss the regulation of GSK3 
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activity by phosphorylation of GSK3’s main regulatory sites that vary depending on the 
isoform/paralog of interest (Beurel et al., 2015).       
Isoforms of Glycogen Synthase Kinase 3 
There are two major paralogs, sometimes referred to as isoforms, of GSK3, one is 
glycogen synthase kinase 3-alpha (GSK3α) and the other is glycogen synthase kinase 3-
beta (GSK3β) which are each produced from their respective genes (Beurel et al., 2015; 
Soutar et al., 2010).  There is a final form of GSK3, which is the product of a splice 
variant of GSK3β, a protein known as GSK3β2.  This splice variant is known to be 
enriched within the neurons of the central nervous system, in particular the brain (Soutar 
et al., 2010).  The activity of GSK3α and GSK3β can be regulated by several different 
mechanisms, however, the phosphorylation of two specific residues, a tyrosine residue 
and a serine residue, are of the greatest importance.  When tyrosine 279 (Tyr279) is 
phosphorylated (pTyr279) in GSK3α the activity of GSK3α is increased and when serine 
21 (Ser21) is phosphorylated (pSer21) the activity is decreased (Fang et al., 2000; 
Medina & Wandosell, 2011). Similarly, if tyrosine 216 (Tyr216) on GSK3β is 
phosphorylated (pTyr216) the activity is increased, and when the serine 9 (Ser9) residue 
is phosphorylated (pSer9) the activity is decreased (Fang et al., 2000; Krishnankutty et 
al., 2017).  Although the isoforms are similar, they have distinct substrate preferences 
(Soutar et al., 2010).  GSK3β has the most predicted substrates than any other kinase, 
with over 500 predicted substrates (Beurel et al., 2015; Linding et al., 2007).  One of the 
substrates of interest, tau (the microtubule-associated protein), has been shown to be a 
substrate for GSK3β, and in the case of disease development, the hyperphosphorylation 
of this protein by GSK3β has been associated with increased pathological outcomes 
(Avila et al., 2012).        
1.5 Glycogen Synthase Kinase 3-beta and Tau 
Phosphorylation of Tau by Glycogen Synthase Kinase 3-beta 
Many studies have investigated the relationship of tau, its phosphorylation by GSK3β, 
and the risk of disease.  In tauopathies, tau is abnormally phosphorylated, above the 
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physiological levels resulting in the production of toxic conformations which form 
aggregates leading to neurofibrillary tangle (NFTs) development (Hanger et al., 2009).  
GSK3β is capable of phosphorylating tau at both primed and un-primed sites (Cho & 
Johnson, 2003), therefore creating more opportunity for increased tau phosphorylation.  
GSK3β displays more activity towards tau and is known to co-localize with 
hyperphosphorylated tau proteins (Tsujio et al., 2000).  The overall levels of GSK3 are 
also increased within Alzheimer’s diseased brains by at least 50% (Tsujio et al., 2000).  
One study investigated the activities of kinases acting on recombinant tau using 
nanoelectrospray mass spectrometry and demonstrated that GSK3β is capable of 
phosphorylating tau at several known sites contained within paired helical filament (PHF) 
tau aggregates (Reynolds et al., 2000).  A desirable goal might be to disrupt or halt the 
process of tau phosphorylation entirely by administering inhibitors to block kinase 
activity (Hanger et al., 2009).        
Inhibitors Prevent Kinase Activity  
The foregoing discussion of GSK3’s role in tau phosphorylation and the role of 
pathological tau phosphorylation in disease suggests that GSK3 inhibition might be an 
attractive strategy for the treatment or prevention of tauopathies.  GSK3β inhibitors can 
be classified into two main categories, one being ATP competitive inhibitors, and the 
other being non-ATP competitive inhibitors (Eldar-Finkelman et al., 2010).  Since ATP 
binding sites are very highly conserved domains in kinases, it is ideal to use non-ATP 
competitive inhibitors in order to increase the specificity for GSK3 proteins and 
minimizing any off-target effects (Eldar-Finkelman et al., 2010).  The most appealing 
non-ATP competitive inhibitors for targeting GSK3 proteins are ones that compete with 
GSK3 substrates for binding, termed substrate competitive inhibitors (Eldar-Finkelman et 
al., 2010).  However, the production of GSK3 inhibitors includes many types of 
chemicals with many different modes of action.  Some of the main groups of inhibitors 
are the maleimides derivatives, aminopyrimidines, the amino thiazoles, and the 
thiadiazolidinones (TDZD) (Cohen & Goedert, 2004; Eldar-Finkelman et al., 2010).  One 
group investigating the effects of GSK3 inhibition on a double transgenic mouse line that 
develops AD-like pathology found that upon inhibition of GSK3β with NP12 (a TDZD, 
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non-ATP competitive), there were decreased levels of phosphorylated tau, and decreased 
cell death (Serenó et al., 2009) among other molecular, cellular, and cognitive benefits.  
Another study investigated the mechanism of GSK3β activation, through the 
phosphorylation of tau at Thr175, that leads to the subsequent phosphorylation of tau at 
Thr231, fibril formation, and cell death (Moszczynski et al., 2015).  Four inhibitors of 
GSK3β were used; lithium chloride, AR-A014418, Tideglusib (aka NP12), and TWS-
119; all of which successfully prevented pathological fibril formation and cell death 
(Moszczynski et al., 2015).         
1.6 Models of Traumatic Brain Injury  
Invertebrate Models 
Caenorhabditis elegans (C. elegans) are nematodes that are considered to be a valued 
model organism (Hill et al., 2000). These metazoans have had their entire genome 
completely sequenced in the 1990s, therefore making genetic studies possible and easily 
accessible (Hill et al., 2000).  One group has studied the effects of surface acoustic waves 
(SAW) in producing similar pathologies in C. elegans comparable to blast induced TBIs 
seen in military and civilians affected by war (Miansari et al., 2019).  This group saw that 
there was decreased mobility and short-term memory impairment upon SAW injury.  
Another model organism are the flies known as Drosophila melanogaster (Adams et al., 
2000).  One team of researchers set out to develop a closed head model of TBI using 
Drosophila melanogaster and discovered that these flies face similar post-TBI injuries 
compared with humans that have suffered from TBI  (Katzenberger et al., 2013).  These 
models offer the benefits of being cheap to maintain, time efficient (with short lifespans), 
and significant knowledge of their genetic backgrounds has been developed 
(Katzenberger et al., 2013; Miansari et al., 2019).  Although these models of TBI have 
useful insights into pathological mechanisms and molecular and cellular cascades that are 
initiated post-injury, there are several drawbacks that must be considered.  For example, 
there are limited tests available to evaluate complex behaviours in these organisms (Shah 
et al., 2019).  Second, these model organisms are too small to administer potential 
therapeutic drugs and observe the effects on behavioural outputs, thereby limiting their 




The effects of TBIs have been investigated using different methods of delivering injuries 
(fluid percussion injury, FPI; controlled cortical impact injury, CCI; weight drop models, 
and blast injuries) and using different animal models (cats, dogs, sheep, rabbits, pigs, 
ferrets, and monkeys) (Xiong et al., 2013). Although the possible combinations may offer 
a lot of insight into the mechanisms behind the pathology of TBIs and disease 
development, there are some drawbacks to consider in using large animal models.  For 
instance, it is difficult to find suitable equipment in order to deliver consistent, precise 
injuries to larger animals. It is also difficult to find enough space to house the animals 
(Cernak, 2005).  Larger animals also mean larger costs for proper housing, care and 
enrichment.  Large animal experiments in TBI may also raise more ethical issues 
(Cernak, 2005).     
Rodent Models  
There is always the struggle of taking results from scientific studies involving animal 
models and then applying them to human beings (Risling et al., 2019).  However, 
technological advancements have allowed the development of genetic tools that have 
been applied to rodents in order to create ideal transgenic models with greater clinical 
relevance to human disease.  Rodents are also ideal models due to the fact that they are 
small, and therefore space efficient, and also able to quickly increase their numbers 
through reproduction to repeatedly run morphological, cellular, biochemical, and 
behavioural analyses (Cernak, 2005).  Several transgenic mouse models have already 
been created in order to tease apart the interactions between rmTBI, GSK3β, and tau.  
The downside of the previous transgenic models is that they fail to express all tau 
isoforms in the same proportions as found in humans, a ratio of 1:1 for 3R:4R 
respectively (Hanes et al, 2009).  As previously mentioned, the balance of the 3R:4R 
ratio of tau isoforms is critical for models of tauopathies, as a disruption to this balance 
can result in tau pathology, without the addition of other factors, and ultimately CTE 
(Hanes et al, 2009; Sergeant, Delacourte, and Buée, 2005).  A rat model of hypertension 
was shown to have different ratios of 3R:4R tau isoforms depending on the brain area of 
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interest (Cortex 1:9, Hippocampus 1:7, and Brainstem 1:6) (Hanes et al, 2009) compared 
to the htau mouse model with an isoform imbalance leaning towards more 3R tau than 4R 
tau (Andorfer et al., 2003).  However, a group of scientists have created a brand new, 
improved mouse model of tauopathy, the MAPT knock-in mouse (MAPT KI mice) (Saito 
et al, 2019).  Overall, the new mouse strain was created by replacing the entire murine 
Mapt genetic sequence with the human MAPT sequence (exons 1-14) through 
homologous recombination.  The targeting construct, including the neomycin-resistant 
gene (neo) flanked with loxP sites, was injected into ES-R1 cells, and once selected the 
positive clones were injected into C57BL/6 blastocysts.  The resulting chimeric mice 
were then crossbred with EIIa CRE mice in order to get rid of the neo gene, and the mice 
were then backcrossed with C57BL/6 mice for 5 generations.  This mouse strain was 
developed in order to express all six human tau isoforms without any expression of 
murine tau, resulting in a tau isoform ratio of approximately 1:0.66 3R:4R (Saito et al, 
2019), which is much closer to that seen in humans.  Therefore, this new mouse strain 
serves as an ideal model for studying the mechanisms of tau phosphorylation in 
tauopathies, and potential avenues for therapeutic targets.  In order to ensure that this 
study is able to capture a more realistic outcome of tau pathology in humans, and 
therefore be more clinically relevant, the MAPT KI mouse strain (Saito et al, 2019) will 
be used.   
1.7 Rationale, Goals and Aims for Thesis  
Rationale  
Repetitive mild traumatic brain injury (rmTBI) is known to be a risk factor for the 
development of neurodegenerative diseases such as Chronic Traumatic Encephalopathy 
(CTE) (Ojo et al., 2013).  It is also known to influence the activity of glycogen synthase 
kinase 3-beta (GSK3β), a kinase with many functions, one of which is to phosphorylate 
tau (Moszczynski et al, 2018).  Previous studies have shown that the activation of 
GSK3β, as a result of brain injury, leads to many detrimental cascades including 
abnormal increases in tau phosphorylation (Moszczynski et al, 2018).  These increases in 
tau phosphorylation are above the natural levels found within cells, and lead to the 
pathology seen in diseased states.  Hyperphosphorylated tau is prone to misfolding, 
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aggregation, fibril formation, and tangle formation, leading to neuron death and other 
pathologies (Polydoro et al., 2009).  The need for a more clinically relevant model of 
rmTBI is an important milestone that must be reached.  By using the newly generated 
humanized MAPT KI mice in this model of closed skull/closed skin rmTBI, we are taking 
one step further towards better understanding the relationships between all of these 
phenomena.     
Goals and Aims for this Thesis  
The overarching goal of this thesis is to validate and characterize a closed skull, closed 
skin model of rmTBI using the MAPT KI mouse. This work will set the stage for future 
studies to evaluate the pathophysiology of rmTBI and to test possible therapeutic 
strategies.   
Goal 
To develop and evaluate a mouse model of concussion in order to study the relationship 
between rmTBI, GSK3β activity, tau phosphorylation, and the development of cognitive 
deficits in a transgenic mouse line expressing solely human tau. 
Aims 
1. To investigate the time course of GSK3β activity in different regions of the brain 
in wildtype rmTBI mice.   
2. To characterize the cellular and molecular pathology in rmTBI MAPT KI mice. 
3. To characterize the behavioural outcomes of rmTBI in the MAPT KI mice, using 
the Elevated Plus Maze (to test for anxiety/anxiety-like behaviours) and the 




Chapter 2  
2 Materials and Methods  
2.1 Animals 
All experiments were approved by the Western University Animal Care Committee 
which adheres to the Canadian Use of Experimental Animal Guidelines. Male and female 
C57BL/6 mice were purchased from Charles River (Quebec, Canada). Male and female 
MAPT KI mice, obtained from Dr. Hashimoto et al. (2019), were bred in house. All mice 
were kept on a 12 hour light : 12 hour dark cycle, and had free access to food and water. 
All experiments were performed during the light cycle. Mice were housed together, with 
a maximum of four mice per cage. 
2.2 Repetitive Mild Traumatic Brain Injury Procedure  
To model concussion in mice in a clinically relevant way, we performed an injury in 
which the skin and skull were kept intact. Mice were randomly assigned to receive either 
a repetitive mild traumatic brain injury (rmTBI), a sham procedure, or to act as naïve 
controls. Before any injuries were delivered, the controlled cortical impact (CCI) device 
(TBI 0310, Precision Systems and Instrumentation) was calibrated to the desired 
experimental parameters.  Mice were then anesthetized using 3% isoflurane for induction 
and maintained on 2% isoflurane using a nose-cone.  The hair on the scalp was shaved 
before the concussion or sham procedure and the mice, along with the nose-cone for 
anesthetic administration, were transferred directly under the CCI device (TBI 0310, 
Precision Systems and Instrumentation) that was used to deliver a mild traumatic brain 
injury.  The tip of the impactor was aligned with the approximate center of bregma. The 
impact was then delivered with a custom-made silicone impactor tip of 4 mm diameter, at 
a programmed velocity of 3.5 m/s, at 1.0 mm depth, and with 500 msec dwell time.  Mice 
were subjected to 5 concussions with a 24 hour inter-injury interval time in order to 
achieve an rmTBI model.  Sham mice underwent 5 minutes of isoflurane anesthesia each 
day for 5 days with a 24 hour interval between sham procedures.  Naïve mice were not 
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manipulated.  Mice were sacrificed at various time points after the final concussion or 
sham procedure.  
2.3 Silver Staining 
The silver staining procedure followed was provided by the manufacturer of the FD 
NeurosilverTM Kit II (FD NeuroTechnologies, Ellicott City, MD). After the coronal brain 
sections (50 m thickness) were stained, they were then promptly mounted on VWR 
microslides (25x75 mm, 1.0 mm thick) and allowed to air dry in the fume hood. Once 
dry, the slides were rinsed in a xylene solution three times, for three minutes each time, 
and then sealed by a cover-slip.  Two slides per animal, containing approximately five 
sections per slide, were selected for analysis.  In total, approximately 3-4 sections per 
animal were visually inspected for positive silver staining.  Slides were imaged using an 
Olympus BX50 brightfield microscope.  Images were taken along the corpus callosum.  
Images were taken for all animals in each experimental group (n’s specified in the 
experimental timelines below).   
2.4 Tissue Preparation for Western Blots 
The mice that were assigned to be used for Western blot analyses were transcardically 
perfused using a chilled saline solution.  Once perfused, brains were extracted and the 
regions of interest, the cortex and the hippocampus, were dissected free of the rest of the 
brain.  The cortex and hippocampus samples were sonicated in RIPA lysis buffer 
supplemented with Halt protease and phosphatase inhibitor cocktail (Life Technologies; 
#78440) at a dilution of 1:100.  The sonicated mixture was then centrifuged at 6000 rpm 
for 20 minutes at 4 °C.  Afterwards, the supernatants were aliquoted into separate tubes 
for storage at -80 °C.  Protein concentrations were determined by a Bradford protein 
assay for each sample in order to load an equal concentration of protein to each lane in 
the Western blots (10 g/lane).    
2.5 Glycogen Synthase Kinase 3 Western Blots  
Mice were sacrificed at various time points after the last impact/sham injury was 
delivered (Refer to Figure 1 and Table 2). A group of naïve mice were also sacrificed to 
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provide an additional control. A standard Western blot protocol was followed (Abcam), 
in which a 10% acrylamide gel was used as the resolving gel, with a 4% acrylamide 
stacking gel. The protein gels ran for approximately one hour at 80 V until samples 
entered the bottom resolving, gel, at which time the voltage was increased to 100 V. 
Western blots were then transferred from the gel to Millipore Immobilon-FL PVDF 
membranes for approximately 1.5-2 hours at 110 V. Membranes were then dried, 
trimmed, and stored at 4 °C overnight. Membranes were then blocked in Intercept 
Blocking Buffer (TBS) from LI-COR for approximately an hour, and then incubated in a 
primary antibody overnight.  To detect β-actin we used either a rabbit anti-β-actin from 
LI-COR Biosciences (#926-42210; Waller et al., 2017) or a mouse anti-β-actin from LI-
COR (#926-42212; Almanzar et al., 2016), each at a dilution of 1:5000, depending on the 
primary antibody used to detect the GSK3β proteins.  To detect total GSK3 (GSK3 TOT) 
we used a mouse anti-GSK3β from BD Transduction Laboratories at a dilution of 1:5000 
as the primary antibody (Lucas et al., 2001).  To detect GSK3β phosphorylated on 
tyrosine 216 (pTyr216) we used a mouse anti-GSK3β pTyr216 from BD Transduction 
Laboratories at a dilution of 1:1000 as the primary antibody (Bhat et al., 2000).  To detect 
GSK3β phosphorylated on Serine 9 (pSer9) we used a rabbit anti-GSK3β pSer9 from 
Biorad at a dilution of 1:1000 as the primary antibody (Stambolic & Woodgett, 1994).  
Membranes were then washed in TBST three times, ten minutes each time, and incubated 
in secondary antibody (either a donkey anti-mouse (680; red) or a donkey anti-rabbit 
(800; green) antibody (LI-COR Bioscience) as appropriate) for an hour. Afterwards, 
membranes were washed in TBST three times (ten minutes each time), and TBS for ten 
minutes. Membranes were imaged using the Odyssey Imaging System (LI-COR 
Bioscience) imaging software.  The relative optical densities of the proteins of interest 
were quantified using ImageStudio Plus software.  Densitometric values for target 
proteins (GSK3 TOT, pTyr216, pSer9) were normalized to the densitometric values for 
β-actin, and then compared to the values obtained for naïve animal samples that were 
present on each blot. Each set of animals, shams and injured, were run on the same set of 
gels. Each set of gels were produced with alternating orders of samples to prevent 
position bias within the gels, which were referred to as “Formats”. Each gel that was 
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produced had the same naïve sample to act as a control across all blots to ensure that 
results could be compared across all gels, and therefore across all time points.  
2.6 Tissue Preparation for Immunohistochemistry  
MAPT KI mice were sacrificed at various time points after the last impact or sham 
procedure (Refer to Figure 2, Table 3, and Table 4). A group of naïve mice were also 
sacrificed to provide an additional control. Mice were perfused with saline, followed by 
4% paraformaldehyde. Brains were dissected and post-fixed in 4% paraformaldehyde 
overnight at 4 °C and then transferred to 20% sucrose solution the next day and left in at 
4 °C overnight. Brains were then patted dry, transferred into plastic brain moulds, 
immersed in OCT, and then stored in the -80 °C freezer. 
The fixed brains were sectioned in the coronal plane on a cryostat. For silver staining 
floating sections at 50 µm thickness were collected. For immunohistochemistry 18 µm 
thick sections were thaw-mounted directly onto slides. Thirty slide sections and ten 
floating sections were collected in an alternating fashion until the desired amount of 
sections were collected.  Floating sections were stored in six-welled plates in 8% 
sucrose/0.5% sodium azide solution and later transferred to 4% paraformaldehyde once 
all of the brains were processed. The floating sections were then processed according to 
the silver staining protocol, mounted on slides, and allowed to dry overnight in the fume 
hood before being sealed by a cover-slip (see above for more details).  Slide sections 
were stored in a labelled box in the -80 °C freezer until they were used for 
immunohistochemical staining.  
2.7 Immunohistochemistry 
AT8, GFAP and IBA1 
Slides were removed from the -80 °C in order to thaw to room temperature for 30 
minutes.  Once thawed, slides were washed in 1xPBS (Phosphate Buffered Saline) twice 
for five minutes each. Slides were then covered in blocking medium (1xPBS, Goat 
Serum, Triton-X-100) for approximately 2 hours and left at room temperature.  The 
primary antibodies, which were diluted in blocking medium, were applied. To detect 
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pathologically phosphorylated tau (phospho-tau (Ser202, Thr205) monoclonal mouse 
AT8 (1:100 dilution) from Invitrogen was used (Y. Zhang et al., 2019).  To detect glial 
fibrillary acidic protein (GFAP) a marker of activated astrocytes a mouse anti-GFAP 
(1:500 dilution) from Sigma was used (Lazarus et al., 2015).  To detect Iba1, a marker of 
microglia, a rabbit anti-Iba1 (1:1000 dilution) from Novus Biologicals was used (Schultz 
et al., 2018). The slides were then “cover-slipped” with a section of parafilm and 
incubated at 4 °C.  The following day, the slides were washed in 1xPBS, three times, for 
30 minutes each.  The slides were then incubated in the appropriate secondary antibody 
(either donkey anti-mouse 595 (Life Technologies) or donkey anti-mouse 488 
(Invitrogen) or donkey anti-rabbit 594 (Invitrogen)) for 45 minutes at a 1:500 
concentration while “cover-slipped” with a new section of parafilm.  After the incubation, 
the slides were washed in 1xPBS three times for 30 minutes each time.  The slides were 
briefly washed in double distilled water before applying VectaShield Hardset Antifade 
Mounting Medium with DAPI (Vector Laboratories, Inc.) and stored at 4 °C.   
Image Analyses 
Two slides, containing approximately five sections per slide, were made for each animal 
in each treatment group.  Out of those sections, 2-3 sections were visually analyzed for 
positive staining.  Slides were imaged using an Olympus BX50 brightfield microscope.  
Images of the prefrontal cortex area were visually analyzed for positive AT8 staining.  
Images of the corpus callosum were visually analyzed for positive GFAP/Iba1 staining.  
All images were taken at 40x magnification, and images were taken of all animals in each 
experimental group (n’s specified in experimental timelines and in related figures).  Dr. 
Kathy Xu of the Brown Lab generously donated representative images of both sham and 
injured C57BL/6 male mice for comparison against the MAPT KI mice.      
2.8 Elevated Plus Maze Test 
Behaviours in both male and female MAPT KI mice were evaluated by the Elevated Plus 
Maze (EPM) test in order to assess anxiety/anxiety-like behaviours (Broussard et al., 
2018).  Eight and a half weeks after the last concussion injury or sham procedure mice 
were placed in the centre of the maze platform facing one of the closed arms and allowed 
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to freely explore for a total of five minutes.  Each mouse had one trial and after the trial 
was concluded the maze was sanitized with 70% ethanol.  The behaviour of each mouse 
in the maze was video recorded and then analyzed using ANY-Maze (Stoelting Co. 
Wood Dale, IL) for the time spent in each of the 3 defined areas (closed arms, open arms, 
centre) as well as the speed, and distance travelled.      
2.9 Morris Water Maze Test 
During the ninth week after the last concussion injury or sham procedure both male and 
female MAPT KI mice underwent evaluation of spatial learning and memory using the 
Morris Water Maze (MWM) (Mannix et al., 2014; Xu et al., 2021).  Training on the 
MWM occurred on four consecutive days (4 trials per training day per mouse).  Each day 
of training had four trails that each had a different starting position corresponding to each 
of the four quadrants in the maze.  The order of the starting positions was changed 
randomly on each training day to prevent repetition.  Mice were placed in the water, 
facing the wall of the maze and allowed to freely swim/explore for a minute per trial. The 
goal of the maze is to locate the hidden transparent platform, placed 1 cm under the 
water, located in quadrant 4.  Successful trials concluded when the mouse located the 
hidden platform and was removed from the maze. Unsuccessful trials, trials in which the 
mouse was unable to find/locate the hidden platform, concluded with the mouse being 
placed on the hidden platform for approximately 20 seconds and then being removed 
from the maze. After the four days of training was completed, a Probe Trial was 
conducted on the fifth day in which the hidden platform was removed from the pool and 
the mice were allowed to freely swim around the pool for one minute. One week after the 
first probe test, mice underwent a retention trial, again with the platform removed, and 
were allowed to swim freely for one minute. For both the probe and retention trials mice 
were placed in quadrant 2, across from the target quadrant, and were only tested for that 
one trial.  The testing information was recorded with a video camera placed above the 
pool area, and analysis was conducted by the ANY-Maze software (Stoelting Co. Wood 
Dale, IL).    
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2.10 Experiment 1: Pilot Study 
Five C57BL/6 mice were used for this study, 2 naïve mice and 3 rmTBI mice (Table 1).  
A depth of 1.0 mm was used during the pilot study in order to determine if this would be 
sufficient enough to cause the desired effect of a mild traumatic brain injury, without 
fracturing the skull. Silver staining was performed in order to assess physical axonal 
damage.  Slides were imaged using an Olympus BX50 brightfield microscope.  The 
corpus callosum was imaged and later assessed, visually, for positive silver staining.  
Table 1. Table outlining the experimental plan for the Pilot Study. 
Group # Tests Sample Size (n) Timepoints Age 
I IHC 2 naïve 2-3 month 




2.11 Experiment 2: GSK3 Study 
 
Figure 1. Timeline of the GSK3 Study. Timeline showing the various timepoints at 
which the male C57BL/6 mice were sacrificed, along with their relative sample sizes 
(n’s).  
  
67 male C57BL/6 mice were used in this study, 6 naïve, 28 sham, and 33 rmTBI mice.  
The outline of the experimental groups can be seen in both Figure 1 and Table 2.  Mice 
were sacrificed at various timepoints, after the last impact or sham procedure, and 
Western blots were used to assess the total amount of GSK3β protein (GSK3 TOT), the 
activation of GSK3β (pTyr216), and the inactivation of GSK3β (pSer9).  Data 
organization was possible with the use of excel spreadsheets.  Statistical analyses were 
performed using Graphpad Prism 8, and data is presented as mean ± SEM.  Western blot 
data were analyzed using a One-way ANOVA test in order to compare across the 
multiple time points that were assessed post-last injury.  Correction for multiple 
comparisons was done using a Tukey’s post hoc test. Statistical significance was set as p 
≤ 0.05.    
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Table 2. Table outlining the experimental plan for the GSK3 Study.  
Group # Tests Sample Size (n) Timepoints Age 
I Western blots 6 naïve naïve 2-3 months 
II, III Western blots 6 sham, 7 rmTBI 8hr 2-3 months 
IV, V Western blots 4 sham, 7 rmTBI 24hr 2-3 months 
VI, V11 Western blots 6 sham, 7 rmTBI 48hr 2-3 months 
VIII, IX Western blots 6 sham, 6 rmTBI 1wk 2-3 months 




2.12 Experiment 3: MAPT KI Study 
 
Figure 2. Timeline of the MAPT KI Study. Timeline showing the various timepoints at 
which the male and female MAPT KI mice were sacrificed, along with their relative 
sample sizes (n’s).   
102 MAPT KI mice were used in this study, 8 naïve, 46 sham, and 48 rmTBI mice.  The 
outline of the experimental groups can be seen in both Figure 2 and Table 3.  Mice were 
sacrificed at various timepoints, after the last impact or sham procedure, and various 
immunohistochemical staining were used to assess cellular and molecular pathology.  
Slides were imaged using an Olympus BX50 brightfield microscope and later assessed, 
visually, for positive silver staining/immunohistochemical staining.  Groups 9, 10, 13, 
and 14 underwent evaluation through the use of various behavioural tests in order to 
assess possible changes in behavioural outcomes post-injury in addition to the various 
immunohistochemical staining.  Data organization was possible with the use of excel 
spreadsheets.  Statistical analyses were performed using Graphpad Prism 8, and data is 
presented as mean ± SEM.  Elevated Plus Maze results were compared using unpaired 
Student’s t-test.  The Morris Water Maze learning curves were analyzed using a Two-
way ANOVA, whereas the time spent in the quadrants was analyzed using a One-way 
ANOVA.  Correction for multiple comparisons was done using a Tukey’s post hoc test. 
Statistical significance was set as p ≤ 0.05. 
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Table 3. Table outlining the experimental plan for the MAPT KI Study.    
Group # Tests Sample Size (n) Timepoints Age 
I 
 II 
IHC Male: 6 naïve   
Female: 2 naïve  
naïve Male: 5-6 months 
Female: 5-6 months 
III, IV IHC Male: 6 sham, 6 rmTBI 24hr Male: 5-6 months 
 
V, VI IHC Male: 6 sham, 6 rmTBI 
 




IHC Male: 6 sham, 6 rmTBI 
Female: 10 sham, 10 rmTBI 
4wk Male: 5-6 months 
Female: 3-5 months 
IX, X 
X111, XIV 
IHC Male: 7 sham, 8 rmTBI 
Female: 11 sham, 12 rmTBI 
10wk Male: 3-5 months 
Female: 3-5 months  
EPM 
MWM 
7 aged MAPT KI mice (5 males and 2 females) and 3 aged C57BL/6 mice (2 males and 1 
female) were used in this study.  The outline of the experimental groups can be seen in 
Table 4.  Slides were imaged using an Olympus BX50 brightfield microscope and later 




Table 4. Table outlining the experimental plan for the aged MAPT KI and C57BL/6 
mice.    
Group # Tests Sample Size (n) Age Strain, Sex 
I IHC 5 14 months MAPT KI, male 
II IHC 1 12 months MAPT KI, female 
III IHC 2 14 months C57BL/6, male 









Chapter 3  
3 Results  
3.1 Pilot Study: To validate a closed head, closed skin model 
of rmTBI 
The goal of this thesis was to characterize a mouse model of concussion that is as 
clinically relevant as possible. In order to accomplish this, it was important that both the 
skull and the skin of the mice remained intact during the entire procedure. Previously 
reported models of TBI in mice were either open skull, requiring a craniotomy (Popovitz 
et al., 2019) or a craniectomy (Giarratana et al., 2019), or closed skull but open skin 
(Bolton & Saatman, 2014; Rehman et al., 2019; Xu et al., 2021).  While these methods 
have the advantage of allowing the site of injury to be precisely located, the fact that the 
skull and skin are not intact in these models makes them less clinically relevant than 
desired.  The Brown laboratory has previously characterized a closed skull, open skin 
model of rmTBI in C57BL/6 mice (Xu et al., 2021). In this model, mice were placed in a 
Kopf mouse anesthesia mask under a traumatic brain injury device (TBI 0310, Precision 
Systems and Instrumentation, LLC). Following a 10 mm midline incision, the skin and 
fascia were reflected. Then the mice received a mild controlled cortical impact directly 
onto the skull, centered on the bregma, with a custom-made, 4mm-diameter pliant 
silicone tip. The impact device was programmed to impact at a depth of 1.0 mm at a 
velocity of 3.5 m/sec with a 500 millisecond dwell time. Each mouse in that study 
received 5 mTBIs (one a day for 5 consecutive days). The purpose of this pilot study was 
to determine if the same injury protocol, without the skin incision, would produce a 
similar level of injury as the open skin rmTBI as assessed by silver staining of the brain 
to detect diffuse axonal injury.   
C57BL/6 mice (n = 3) were subjected to 5 mTBIs (one a day for 5 days) and sacrificed 10 
days post-last injury.  A group of unmanipulated mice (n = 2) acted as naïve controls.  An 
examination of tissue sections from injured and naïve mice demonstrated that the injured 
mice had significant levels of silver stained axons within the corpus callosum (Figure 3C) 
and even more so in the optic tract (Figure 3D) compared to the naïve controls (Figure 
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3A and B).  When compared to the mice injured in the same way but with the scalp 
reflected away (Figure 3E and F), there was less silver staining in the corpus callosum 
and more robust staining in the optic tract. This suggested that the rmTBI with closed 
skin produces a similar injury as the open skin injury with the impact device settings of 
1.0 mm depth, 3.5 m/sec velocity and 500 millisecond dwell time, just in different 
regions of the brain.  Therefore, the rmTBI with the skin intact, was shown to produce 




Figure 3. Silver staining during the pilot study. (A) Silver staining of the corpus callosum 
of a naïve animal (n=2). (B) Silver staining of the optic tract of a naïve animal. (C) Silver 
staining of the corpus callosum of a closed skin injured animal (n=3). (D) Silver staining 
of the optic tract of a closed skin injured animal.  (E) Silver staining of the corpus 
callosum of an open skin injured animal.  (F) Silver staining of the optic tract of an open 




3.2 Aim #1: To determine the kinetics of GSK3β 
phosphorylation post-rmTBI in the C57BL/6 mice 
GSK3β has been identified as a kinase critical to the pathological phosphorylation of tau 
(Hooper et al., 2008; Moszczynski et al., 2018).  In vitro GSK3β inhibition prevents 
pathological tau phosphorylation and promotes cell survival (Moszczynski et al., 2015). 
The regulation of GSK3β depends on the phosphorylation status of two regulatory sites, 
Tyr216 and Ser9.  When Tyr216 becomes phosphorylated (pTyr216), the activity of 
GSK3β is increased, however, when Ser9 becomes phosphorylated (pSer9), the activity 
of the kinase is blocked (Soutar et al., 2010).  As one of the ultimate goals of this model 
development, to test whether GSK3 inhibition may be a strategy to prevent pathological 
tau accumulations in the concussed brain, we sought to describe the kinetics of GSK3β 
phosphorylation on both the Tyr216 and the Ser9 sites at various time points after rmTBI. 
In this study Western blots were used to assess the levels of GSK3β protein (GSK3 
TOT), pTyr216, and pSer9 in the cortex and hippocampus of naïve, sham, and rmTBI 
mice (n= 4-7 per group). The levels of GSK TOT, pTyr216 and pSer9 were analyzed 
relative to the levels of -actin.  The levels of pTyr216 and pSer9 were also analyzed as a 
ratio to GSK TOT. 
Western blot analyses of cortical samples when protein levels were normalized to -actin 
Western blot analyses of total amount of GSK3β protein in naïve, sham and rmTBI 
cortices revealed that the levels of GSK3 TOT were higher in shams than in naïves at 8 h 
and 1 week post-injury (Figure 4A). Similarly, the levels of GSK3 TOT were higher in 
rmTBI mice than in naïves at 8 h, 1 week and 3 week post-injury (Figure 4A). The 
Western blot analyses also showed higher pTyr216 levels in both shams and rmTBI mice 
compared to naïves across all time points with the exception of shams at 8 h post-
procedure (Figure 4B).  The Western blot analyses also showed increased levels of pSer9 
in shams at 3 weeks post-procedure compared to naïves and at 48 h and 3 week post-
injury in the rmTBI group compared to naïves (Figure 4C).  There were no time points at 
which GSK TOT or pTyr216 levels were significantly different between sham and rmTBI 
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mice, however, pSer9 levels were significantly higher in rmTBI mice compared to shams 
at 48 h post-injury. 
 
Figure 4. Western blot data for the cortex samples across all timepoints. (A) Graph 
shows all treatment groups (naïve, sham and injured) for each timepoint looking at the 
total amount of GSK3β, GSK3 TOT, relative to β-actin and then compared to the naïve 
sample. (B) Graphs focus on the amount of phosphorylation at the Tyr216 site on GSK3β 
relative to β-actin and then compared to the naïve sample. (C) Graphs focus on the 
amount of phosporylation at the Ser9 site on GSK3β relative to β-actin and then 
compared to the naïve sample.  (D) Respresentative Western blots (n=naïve, s=sham, 
h=hit).  Data were presented as mean±SEM. SEM was presented as the error bars. One-
way ANOVA statistical tests were performed with Tukey’s multiple comparisons test, 
p<0.05.  “*” represents treatment groups that significantly differ from the naïve animals. 





Western blot analyses of hippocampal samples when protein levels were normalized to -
actin 
Western blot analyses of total amount of GSK3β protein in naïve, sham and rmTBI 
hippocampi revealed that the levels of GSK3 TOT were higher in sham and rmTBI 
hippocampi than in naïve hippocampi at 24 h post-injury or sham procedure (Figure 5A). 
The Western blot analyses also showed higher pTyr216 levels in both shams and rmTBI 
mice compared to naïves across all time points with the exception of the 3 week time 
point post-procedure (Figure 5B).  Compared to naïves the levels of pSer9 was higher in 
shams at 48 h and 1 week post-sham procedure and in rmTBI mice at 1 week post-injury 
(Figure 5C).  There were no time points at which GSK TOT or pTyr216 levels were 
significantly different between sham and rmTBI mice, however, pSer9 levels were 





Figure 5. Western blot data for the hippocampal samples across all timepoints. (A) 
Graph shows all treatment groups (naïve, sham and injured) for each timepoint looking at 
the total amount of GSK3β, GSK3 TOT, relative to β-actin and then compared to the 
naïve sample. (B) Graphs focus on the amount of phosphorylation at the Tyr216 site on 
GSK3β relative to β-actin and then compared to the naïve sample. (C) Graphs focus on 
the amount of phosporylation at the Ser9 site on GSK3β relative to β-actin and then 
compared to the naïve sample.  (D) Respresentative Western blots (n=naïve, s=sham, 
h=hit).  Data were presented as mean±SEM. SEM was presented as the error bars. One-
way ANOVA statistical tests were performed with Tukey’s multiple comparisons test, 
p<0.05.  “*” represents treatment groups that significantly differ from the naïve animals. 
“#” represents significant differences between the sham and injured groups of the same 
timepoint. 
Western blot analyses of cortical samples when protein levels were normalized to GSK 
 
To evaluate the relative level of GSK3 activation in the cortex we also examined the 
ratio of pTyr216 levels to GSK TOT levels in cortical protein samples.   These analyses 
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revealed that the levels of pTyr216, when normalized to GSK TOT levels, was 
significantly reduced by approximately 2-fold, in sham and rmTBI mice compared to 
naïves at all time points studied (except for the shams at 3 week post-procedure) (Figure 
6A).  To evaluate the relative level of GSK3 inhibition we also examined the ratio of 
pSer9 levels to GSK TOT levels in cortical protein samples.   We found that pSer9 levels 
in sham mice, when normalized to GSK TOT levels were significantly reduced (by 5 – 10 
fold) compared to naïves at 8 h, 24 h, 48 h and 1 week post-procedure (Figure 6B).  The 
pSer9 levels in the rmTBI mice, when normalized to GSK TOT levels, were significantly 
reduced (by 5 – 10 fold) compared to naïves at 8 h and 24 h, post-injury (Figure 6B). 
Western blot analyses of hippocampal samples when protein levels were normalized to 
GSK  
To evaluate the relative level of GSK3 activation in the hippocampus we examined the 
ratio of pTyr216 levels to GSK TOT levels in the hippocampal protein samples.   This 
analyses revealed that the levels of pTyr216, when normalized to GSK TOT levels, was 
significantly reduced by approximately 4-5-fold, in sham and rmTBI mice compared to 
naïves at all time points studied (except for the 3 week post-injury or procedure time 
point) (Figure 6C).  To evaluate the relative level of GSK3β inhibition we also examined 
the ratio of pSer9 levels to GSK TOT levels in cortical protein samples.   We also found 
that pSer9 levels in sham mice, when normalized to GSK TOT levels were significantly 




Figure 6. Western blot data comparing the amount of phosphorylation at the regulatory 
sites on GSK3β to the total amount of GSK3β protein. (A) Cortex samples for all 
treatment groups across all the timepoints analyzed focusing on the amount of 
phosphorylation at the Tyr216 regulatory site, relative to the total amount of protein. (B) 
Cortex samples for all treatment groups across all the timepoints analyzed focusing on 
the amount of phosphorylation at the Ser9 regulatory site, relative to the total amount of 
protein.  (C) Hippocampus samples for all treatment groups across all the timepoints 
analyzed focusing on the amount of phosphorylation at the Tyr216 regulatory site, 
relative to the total amount of protein.  (D) Hippocampus samples for all treatment 
groups across all the timepoints analyzed focusing on the amount of phosphorylation at 
the Ser9 regulatory site, relative to the total amount of protein.  (E) Hippocampus 
samples from (D) excluding the naïve animals.  Data were presented as mean±SEM. 
SEM represented as the error bars. One-way ANOVA statistical tests were performed 
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with Tukey’s multiple comparisons test, p<0.05. “*” represents treatment groups that 
significantly differ from the naïve animals. “#” represents significant differences between 
the sham and injured groups of the same timepoint. 
3.3 Aim #2: To characterize the cellular and molecular 
pathology triggered by rmTBI in the MAPT KI mice 
MAPT KI mice 
As discussed in the introduction to this thesis (Chapter 1, pages 1-23), using MAPT KI 
mice to study rmTBI increases the clinical relevance of this model of rmTBI. The MAPT 
KI mice carry a fully humanized tau gene in place of the murine tau gene. Thus, 
pathological consequences of concussion due to the effects of rmTBI on tau would be 
predicted to be more reflective of human pathological changes consequent to concussion 
in the MAPT KI mice compared to C57BL/6 mice.  
A COVID19 impact note concerning the histopathological and behaviour analyses below 
During the analyses phase of this study it became apparent that the controlled cortical 
impactor was not performing up to specifications, despite being calibrated by myself and 
others in the laboratory. There was a problem with the impactor itself, in that the speed 
and/or depth programming of the machine was incorrect and highly variable. The 
impactor was sent back to the company (Precision Instruments) for recalibration but was 
damaged in transit back to the Robarts Research Institute and we now are awaiting a 
replacement. I wanted to repeat the experiment with a properly calibrated impactor 
however, the combined effects of the COVID-19 restrictions on animal work instituted in 
March of 2020 and the impactor malfunction delayed my progress by 6 – 8 months 
making it impossible for me to repeat.  Thus, I present my findings below with the 
admission that there was great variability in the injuries carried out in the MAPT KI 
mice that makes interpretations of the data challenging at best.  However, I carried out 
the histopathological and behavioural analyses to the best of my ability and have, at the 
very least, provided baseline measurements for shams and naïves that will be useful when 





To assess MAPT KI mice for histological changes after rmTBI that reflect diffuse axonal 
injury (DAI) we performed silver staining of brain sections from MAPT KI mice taken at 
various time points after injury using the FD NeurosilverTM Kit II silver staining kit (FD 
NeuroTechnologies, Ellicott City, MD) as previously described (Xu et al., 2021).  Images 
of the corpus callosum were taken using a brightfield microscope at 40x and were 
visually inspected for black silver staining (Figure 7-10).  
Short term analyses (naïve, 1 and 7 days) 
Naïve animals had no intervention during the experiment, and as expected, had no 
evidence of silver stained axons when looking at the corpus callosum (Figure 7A). At 1 
day and 7 days post-injury, brain sections from injured male MAPT KI (Figure 7C and E) 
demonstrated some silver staining, compared to shams (Figure 7B and D) that was 




Figure 7. Silver staining for the short term timepoints of the MAPT KI study. (A) Silver 
staining of the corpus callosum of a naïve animal (n=6). (B) Silver staining of the corpus 
callosum of a sham animal sacrificed at the 1 day timepoint.  (C) Silver staining of the 
corpus callosum of an injured animal sacrificed at the 1 day timepoint.  (D) Silver 
staining of the corpus callosum of a sham animal sacrificed at the 7 day/1 week 
timepoint.  (E) Silver staining of the corpus callosum of an injured animal sacrficed at the 




Long term analyses (4 and 10 weeks)  
Sections from both male and female injured MAPT KI mice demonstrated some silver 
staining at 4 and 10 week post-injury compared to their sham counterparts (Figure 8).  
High power magnifications showed that the silver stained axons had the characteristic 
tortuous appearance suggestive of axonal damage (Shitaka et al., 2011).   
 
Figure 8. Silver staining for the longer term timepoints of the MAPT KI study. (A) Silver 
staining of the corpus callosum of a sham male sacrificed at the 4 week timepoint. (B) 
Silver staining of the corpus callosum of an injured male sacrificed at the 4 week 
timepoint.  (C) Silver staining of the corpus callosum of a sham female sacrificed at the 4 
week timepoint.  (D) Silver staining of the corpus callosum of an injured female 
sacrificed at the 4 week timepoint.  (E through H) Same order of images as the ones 
above, except taken from the animals sacrifced at the 10 week timepoint. All images were 
taken at 40x.  
Variability in injury  
While the histopathological staining of rmTBI MAPT KI mice showed the presence of 
silver-stained axons their number per section seemed greatly reduced compared to the 
number of silver-stained axons in the pilot project described above.  Furthermore, we also 
observed a great degree of variability in the amount of silver staining in different mice.   
This variability can be seen in the images in Figure 9.  Figure 9 shows the results of silver 
staining in sections from 4 different males and 4 different females 10 weeks after their 
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injury.  Despite receiving the same injury, the silver staining revealed great variability in 
the number of silver stained axons between animals. Most of the animals studied had 
minimal silver staining (Figure 9A, B, C, E, F and G) suggesting lighter concussive hits, 
whereas a handful of injured animals had greater amounts of silver staining suggesting 
that they sustained more severe injuries (Figure 9D and H), resulting in more pathology. 
Naïve animals did not show signs of positive silver staining.  This histopathology was the 
first inkling that the impactor was malfunctioning – a problem that was subsequently 
verified and prompted a return of the impactor to Precision Instruments for recalibration 
and repair. 
 
Figure 9. Silver staining of the variabliltiy of the injuries delivered by the controlled 
cortical impactor (CCI). (A through D) Snippets of the corpus callosum of the injured 
male animals sacrifficed at the 10 week timpoint. (E through H) Snippets of the corpus 
callosum of the injured females sacrifced at the 10 week timepoint. Images on the left 
most side have negligible silver staining and as the images move towards the right most 
side there is significant amounts of silver staining. Images in the middle vary in the 
degree of silver staining. Images were taken at 40x. 
Silver staining in sections from Aged MAPT KI mice  
To fully characterize the usefulness of the MAPT KI mice for chronic studies of rmTBI 
there was a need to establish baseline histopathological measures in uninjured aged 
MAPT KI mice.  All aged animals received no intervention during these experiments.  
Male MAPT KI mice were raised until they reached 14 months of age and were then 
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sacrificed.  A single female MAPT KI mouse was raised until it reached 12 months of age 
and was then sacrificed.  Greater numbers of MAPT KI mice were not available due to 
COVID-19 restrictions on animal breeding.  Both aged male and female MAPT KI mice 
displayed minimal silver staining (Figure 10A and B) that was comparable to the amount 
of silver staining observed in aged (14 month old) C57BL/6 mice (Figure 10C and D).   
 
Figure 10. Silver staining of the aged animals. (A) Silver staining of the corpus callosum 
of an aged MAPT KI male sacrificed at 14 months old. (B) Silver staining of the corpus 
callosum of an aged MAPT KI female sacrificed at 12 months old.  (C) Silver staining of 
the corpus callosum of an aged C57BL/6 male sacrificed at 14 months old.  (D) Silver 
staining of the corpus callosum of an aged C57BL/6 female sacrificed at 14 months old. 
All images were taken at 40x.  
Staining for pathologically phosphorylated tau in injured MAPT KI animals 
Abnormal phosphorylation of tau has been reported in human brain samples from 
subjects with a history of concussion (McKee et al., 2009, 2013; Tagge et al., 2018) and 
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in rmTBI mice (Tagge et al., 2018; Xu et al., 2021).  To characterize the levels of 
pathologically phosphorylated tau in rmTBI MAPT KI mice we immunostained sections 
from naïve, sham and rmTBI mice at 10 weeks post-injury or sham procedure with the 
AT8 antibody that recognizes phospho-tau (Ser202, Thr205) (Y. Zhang et al., 2019). 
Figure 11 shows a series of photomicrographs taken in the cortical/prefrontal areas of 
these sections.  Naïve male MAPT KI did not display positive AT8 staining (Figure 11D).  
Injured male MAPT KI mice (Figure 11F) had significantly more AT8 positive staining 
compared to the shams (Figure 11E) and the naïve animals (Figure 11D) that was 
comparable to the AT8 staining seen in C57BL/6 rmTBI mice (Figure 11C).   
 
Figure 11. AT8 staining in the prefrontal cortex of the injured animals. (A) 
Representative ATLAS image of the brain sections that were stained and imaged. The 
black box represents the approximate area in which the photos were taken. AT8 staining 
is red and DAPI staining is blue. (B) Image of a C57BL/6 sham animal donated by Dr. 
Kathy Xu for comparison to the MAPT KI.  (C) Image of a C57BL/6 injured animal 
donated by Dr. Kathy Xu for comparison to the MAPT KI.  (D) Image of a naïve MAPT 
KI animal. (E) Image of a sham MAPT KI animal.  (F) Image of an injured MAPT KI 
animal.  Numbers in the top right corner represent the n’s for each group. All images 




Staining for pathologically phosphorylated tau in uninjured aged MAPT KI animals 
To fully characterize the usefulness of the MAPT KI mice for chronic studies of rmTBI 
there was also a need to establish baseline levels for pathologically phosphorylated tau in 
aged MAPT KI mice.  We immunostained brain sections from aged uninjured MAPT KI 
mice with the AT8 antibody. Figure 12 shows photomicrographs taken from the 
cortical/prefrontal areas of these sections (Figure 12A).  Aged animals were not 
manipulated and left to age naturally over the course of this experiment.  C57BL/6 male 
and female mice were aged to 14 months old, male MAPT KI mice were aged to 14 
months old, and the sole female MAPT KI mouse was aged to 12 months.  Naïve animals 
did not show any positive AT8 staining (Figure 12D).  Uninjured, aged male and female 
C57BL/6 mice showed minimal AT8 staining (Figure 12B and C), whereas uninjured, 
aged male and female MAPT KI mice demonstrated more AT8 positive staining (Figure 






Figure 12. AT8 staining in the prefrontal cortex of the aged animals. (A) Representative 
ATLAS image of the brain sections that were stained and imaged. The black box 
represents the approximate area in which the photos were taken. AT8 staining is red and 
DAPI staining is blue. (B) Image of an aged C57BL/6 male sacrificed at 14 months old. 
(C) Image of an aged C57BL/6 female sacrificed at 14 months old.  (D) Image of a naïve 
MAPT KI animal. (E) Image of an aged MAPT KI male sacrificed at 14 months old. (F) 
Image of an aged MAPT KI female sacrificed at 12 months old. Numbers in the top right 
corner represent the n’s for each group. All images were taken at 40x.  
Inflammation in the MAPT KI mice after rmTBI  
To determine if the inflammatory response triggered by rmTBI in MAPT KI mice was 
similar to that triggered in rmTBI C57BL/6 mice we immunostained brain sections from 
rmTBI (C57BL/6 and MAPT KI) mice for GFAP and Iba1.  Figure 13 shows 
photomicrographs from the cortex of these stained sections (Figure 13A).  Injured male 
C57BL/6 and MAPT KI (Figure 13C and H) mice displayed increased levels of Iba1 
immunostaining compared to sham animals (Figure 13B, D, G and J).  Naïve male MAPT 
KI mice (and C57BL/6 mice, data not shown) did not show any significant Iba1 staining 
(Figure 13F), but did show moderate GFAP staining (Figure 13I) as did sections from 




Figure 13. GFAP and Iba1 staining in the corpus callosum area for the injured animals. 
(A) Representative ATLAS image of the brain sections that were stained and imaged. 
The black box represents the approximate area in which the photos were taken. GFAP 
staining is green, Iba1 staining is red and DAPI staining is blue.  (B and D) Images of the 
GFAP and Iba1 staining for a C57BL/6 sham animal donated by Dr. Kathy Xu. (C and E) 
Images of the GFAP and Iba1 staining for a C57BL/6 injured animal donated by Dr. 
Kathy Xu. (F and I) Images of the GFAP and Iba1 staining for a naïve MAPT KI animal. 
(G and J) Images of the GFAP and Iba1 staining for a sham MAPT KI animal.  (H and K) 
Images of the GFAP and Iba1 staining for an injured MAPT KI animal.  Numbers in the 




What does the GFAP and Iba1 staining look like in uninjured aged MAPT KI mice 
To fully characterize the usefulness of the MAPT KI mice for chronic studies of rmTBI 
we investigated the baseline GFAP and Iba1 levels in brain sections from uninjured aged 
MAPT KI mice. Brain sections from uninjured, aged MAPT KI mice were immunostained 
for GFAP and Iba1 expression.  Figure 14 shows photomicrographs taken from the cortex 
of these sections (Figure 14A).  While aged, uninjured C57BL/6 and MAPT KI mice 
demonstrated very little Iba1 expression (Figure 14B, C, G and H) they did demonstrate 




Figure 14. GFAP and Iba1 staining in the corpus callosum area for the aged animals. (A) 
Representative ATLAS image of the brain sections that were stained and imaged. The 
black box represents the approximate area in which the photos were taken. GFAP 
staining is green, Iba1 staining is red and DAPI staining is blue.  (B and D) Images of the 
GFAP and Iba1 staining of an aged C57BL/6 male. (C and E) Images of the GFAP and 
Iba1 staining of an aged C57BL/6 female. (F and I) Images of the GFAP and Iba1 
staining for a naïve MAPT KI animal. (G and J) Images of the GFAP and Iba1 staining of 
an aged MAPT KI male. (H and K) Images of the GFAP and Iba1 staining of an aged 
MAPT KI female. Numbers in the top right corner represent the n’s for each group. All 




3.4 Aim #3: To characterize the behavioural outcomes 
triggered by rmTBI in the MAPT KI mice 
The effects of rmTBI on behaviour of MAPT KI mice in the elevated plus maze  
It has been previously shown that rmTBI can be associated with anxiety and anxiety-like 
behaviours post-injury (Broussard et al., 2017).  We sought to investigate the potential 
effects of rmTBI on anxiety/anxiety-like behaviours at 8.5 weeks post-injury in the 
MAPT KI mice using the Elevated Plus Maze (EPM) test.  Mice were placed into the 
centre portion of the maze and allowed to freely explore the maze as their behaviours 
were videotaped for five minutes.  The amount of time each mouse spent in the closed 
arms, open arms, and in the centre of the maze was measured by ANY-Maze (Stoelting 
Co. Wood Dale, IL).  Male rmTBI MAPT KI mice spent a significantly longer amount of 
time in the closed arms compared to the shams (Figure 15A), which spent more time in 
the open arms of the maze (Figure 15B). There were no significant differences in the 
amount of time spent in the centre part of the maze (Figure 15C).  There were no 
significant differences in the mean speed, and total distance travelled between the male 
sham and rmTBI MAPT KI mice (Figure 16A and B). 
An analysis of female rmTBI and sham MAPT KI mice demonstrated there were no 
significant differences in the amount of time spent in the closed and open arms of the 
maze (Figure 15D and E), however, there were significant differences in the amount of 
time spent in the centre part of the maze (Figure 15F).  The female rmTBI mice spent a 
significantly longer time in the centre of the maze compared to shams.  There were 
significant differences in the mean speed and total distance travelled (Figure 16C and D) 
with the female sham mice travelling at a faster mean speed than the injured females and 





Figure 15. Behavioural data from the Elevated Plus Maze (EPM) Test. (A) Time spent in 
the closed arms of the EPM for sham and injured MAPT KI males. (B) Time spent in the 
open arms of the EPM for sham and injured MAPT KI males. (C) Time spent in the 
centre area of the EPM for sham and injured MAPT KI males. (D) Time spent in the 
closed arms of the EPM for sham and injured MAPT KI females. (E) Time spent in the 
open arms of the EPM for sham and injured MAPT KI females. (F) Time spent in the 
centre area of the EPM for sham and injured MAPT KI females. Data were presented as 
mean±SEM. SEM was represented as the error bars. “*” represents significant 
differences between the treatment groups. Student’s t-test was performed for the EPM 




Figure 16. Mean speed and total distance travelled in the Elevated Plus Maze (EPM) 
Test. (A) Mean speed of sham and injured MAPT KI males. (B) Total distance travelled 
for sham and injured MAPT KI males. (C) Mean speed of sham and injured MAPT KI 
females. (D) Total distance travelled for sham and injured MAPT KI females. Data were 
presented as mean±SEM. SEM was represented as the error bars. “*” represents 
significant differences between the treatment groups. Student’s t-test was performed for 
the EPM data, p<0.05   
  
How does rmTBI influence spatial cognition and memory of MAPT KI mice?  
Repetitive mTBI has been previously linked to spatial cognition and memory deficits 
using the Morris Water Maze test (MWM) (Mannix et al., 2014; Xu et al., 2021).  The 
effects of rmTBI on spatial cognition and memory in male and female MAPT KI mice 
were assessed with the MWM.  Male sham and rmTBI MAPT KI mice had difficulty 
learning the task, as demonstrated by the learning curves in Figure 17A [F(3,48)=1.849, 
p=0.1510].  During the Probe Trial, conducted on Day 5, there were no significant 
differences in the amount of time spent in the target quadrant versus non-target quadrants 
as assessed by one-way ANOVA (Figure 17B).  There was a significant difference seen 
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in the mean swim speeds (m/sec) during the Probe Trial, with the injured males 
swimming significantly faster than the sham males (Figure 17C).   
The learning curves for the female sham and rmTBI MAPT KI mice demonstrate that 
both groups were able to learn the task, with no significant differences in learning 
between groups throughout the four training days (Figure 17D). On the Probe Trial there 
were no significant differences in the amount of time spent in the target quadrant versus 
non-target quadrants as assessed by one-way ANOVA (Figure 17E), for sham or rmTBI 
MAPT KI females. There were no significant differences for swim speeds between 
groups during the Probe Trial (Figure 17F).   
 
Figure 17. Behavioural data from the Morris Water Maze (MWM) Test. (A) Escape 
latency for each of the four training days of the MWM for both sham and injured MAPT 
KI males. (B) Time spend in both the non-target (Q1-3) and target (Q4) quadrants of the 
MWM during the probe trial for both sham and injured MAPT KI males. (C) Mean swim 
speed for sham and injured MAPT KI males. (D) Escape latency for each of the four 
training days of the MWM for both sham and injured MAPT KI females. (E) Time spend 
in both the non-target (Q1-3) and target (Q4) quadrants of the MWM during the probe 
trial for both sham and injured MAPT KI females. Data were presented as mean±SEM. 
SEM was represented as the error bars. “*” represents significant differences between the 
treatment groups. One-way ANOVA statistical tests were performed for A, B, D, and E 




Chapter 4  
4 Discussion and Conclusions 
The objectives of this study were to characterize a time course of GSK3β 
phosphorylation, using C57BL/6 mice, and to investigate the cellular/molecular 
pathology and behavioural outcomes in MAPT KI mice in order to validate their 
usefulness in concussion research as a more clinically relevant model.  This study is 
going to be one of few, if not the first of its kind, to use the MAPT KI transgenic mice 
created from Saito et al. (2019) in a model of repetitive mild traumatic brain injury.   
4.1 Pilot Study 
Before the study began, a pilot study was conducted in order to determine if the same 
injury protocol, minus the skin incision, would produce similar injury levels compared to 
the injury protocol including the skin incision previously used by the Brown Lab (Xu et 
al., 2021).  Silver staining revealed that both injury protocols produced abundant positive 
silver staining, but in different areas of the brain (Figure 3), proving that keeping the skin 
intact with the same injury parameters was sufficient to cause physical axonal damage. 
Clearly, the protocol excluding the skin incision was sufficient to produce some level of 
injury as indicated by the silver staining, however, in the future, there could be room for 
improvement.  For instance, the parameters of the hit could be adjusted to account for the 
thickness of the skin and/or adjust the intensity of the injury delivered.  One study 
investigating the physical and mechanical properties of mammalian skin in various 
animal models determined that smaller species, such as rodent models, have increased 
viscoelastic effects in the skin compared to larger species, such as humans (Wei et al., 
2017).  Other factors can also influence the properties of the skin, such as age, gender, 
and weight (Wei et al., 2017).  In terms of the actual injury parameters, both the depth 
and the speed of the injury delivered could be adjusted in order to increase the severity of 
the hit.  This could be done by increasing the depth or by increasing the speed, or by 
increasing both parameters at the same time.   
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4.2 Kinetics of GSK3β Phosphorylation triggered by rmTBI 
After an episode of rmTBI, many cascades are initiated that result in neurodegenerative 
changes that lead cognitive deficits.  It has been proposed that GSK3β is responsible for 
the abnormal phosphorylation of tau in tauopathies, such as CTE (Hooper, Killick, and 
Lovestone, 2008).  This abnormal phosphorylation of tau is what causes the pathological 
formation of aggregates/fibrils/tangles leading to neuronal death (Polydoro et al., 2009).  
Moszczynski et al (2018) demonstrated this process, in a rodent model of moderate TBI, 
showing that both the activation of GSK3β and tau pathology were increased 3 months 
post-injury.  Many studies have evaluated the effects of preventing the activation of 
GSK3β and abnormal tau phosphorylation (Dash et al., 2011).  To plan how we might 
best deliver a GSK3β inhibitor we sought to determine when and for how long, after 
rmTBI, GSK3β is activated.  In my study, several time points post-injury were analyzed 
to investigate the levels of phosphorylation on two of the main regulatory sites on 
GSK3β, pTyr216 and pSer9 (Fang et al., 2000; Krishnankutty et al., 2017), relative to 
total GSK3β.  Western blot analyses revealed that in both the cortical and hippocampal 
protein samples GSK3 TOT levels when normalized to β-actin were increased in rmTBI 
mice compared to naïves at several timepoints (Figure 4 and 5).  When looking at the 
relative phosphorylation on the regulatory sites compared to total GSK3β protein (Figure 
6), there is a higher ratio of pTyr216/GSK3 TOT compared to pSer9/GSK3 TOT, and, 
taken together with the increase in total GSK3β protein, these results suggest that there 
may be increased activation of GSK3β in the rmTBI groups.  However, these two 
regulatory sites are not the only regulatory mechanisms acting on GSK3β.  For example, 
there is another known inhibitory site on GSK3β, Ser389, that is phosphorylated by p38 
mitogen-activated protein kinase (MAPK) (Thornton et al., 2008).  In order to assess the 
actual activity of GSK3β, kinase activity assays would need to be conducted, similar to 
that seen in the Noble et al. study (Noble et al., 2005).  In the future, one could also 
assess the activity of multiple activation and inactivation pathways that converge on 
GSK3β in order to get a clearer, more complete picture as to how active GSK3β actually 
is during pathological processes.  Two of the main signaling pathways that result in the 
inactivation of GSK3 proteins are the insulin and Wnt pathways (Beurel et al., 2015).      
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GSK3β also requires substrate priming for the majority of its known substrates.  Priming 
of target substrates is a method of controlling the specificity and targeting action of 
GSK3β (Fiol et al., 1987).  This priming mechanism involves the phosphorylation of 
GSK3β substrates by another kinase at approximately 4 residues away from the target site 
for GSK3β phosphorylation (Frame & Cohen, 2001).  Therefore, it would be of great 
interest to investigate the priming kinases that phosphorylate before GSK3β, as these 
kinases must act first in order for GSK3β to perform the subsequent phosphorylation(s) 
(Frame & Cohen, 2001).     
Another method of assessing the contribution of GSK3β to the development of 
pathological hallmarks of disease would be to conduct inhibitory trials where the activity 
of GSK3β is hindered or completely blocked.  A potential candidate GSK3β inhibitor, 
such as lithium, could be administered in order to mitigate these pathological 
mechanisms/pathways from occurring and deter cognitive impairments associated with 
multiple mild traumatic head injuries (concussions) (Dash et al, 2011).  In a cell culture 
experiment using Neuro2A cells, Moszczynski et al (2015) demonstrated that lithium 
treated cultures showed reduced GSK3β activity, decreased tau phosphorylation, 
reducing fibril formation and cell death.   
It is worthy to note that other tau kinases may be responsible and contribute to the 
abnormal phosphorylation of tau.  Each kinase involved in the phosphorylation of tau 
phosphorylates specific target sites that consequently result in unique physiological 
effects, some of which may be pathological (Dolan & Johnson, 2010).  For example, a 
study investigating paired helical filament tau (PHF-tau) using mass spectrometry found 
that casein kinase 1 delta (CK1δ) phosphorylated approximately 15 sites implicated in 
PHF-tau (Hanger et al., 2007).  The number of sites that CK1δ was capable of 
phosphorylating on PHF-tau was comparable to that of GSK3β in this study, 
demonstrating that other tau kinases, or synergistic relationships between tau kinases, 
might be implicated in the generation of pathological tau aggregates (Hanger et al., 
2007).  Another kinase that may phosphorylate tau is cyclin dependent kinase 5 (cdk5) 
(Baumann et al., 1993).  In this study, investigators evaluated  cyclin dependent kinase 
(cdk) family members that are expressed within the brain and found a cdk-like kinase that 
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was able to phosphorylate tau in a similar manner to pathological tau present in 
Alzheimer’s disease (AD) (Baumann et al., 1993).  They discovered cdk5, confirming its 
presence with the use of cdk5 specific antibodies, and proposed that this kinase be 
considered as a serious contender for potential pathological phosphorylation of tau. Fyn, 
a tyrosine kinase, is also capable of phosphorylating human tau (at the tyrosine 18 
(Tyr18) residue) (G. Lee et al., 2004).  Fyn has been shown to co-localize with 
pathologically phosphorylated tau protein, in particular, PHF-tau that reacts positively 
with antibodies targeting the Tyr18 site (G. Lee et al., 2004).  Therefore, Fyn is another 
important candidate for causing or contributing to the abnormal phosphorylation of tau. 
It is important to recognize that both the sham and injured mice in this study displayed 
similar changes in the phosphorylation status of the two regulatory sites.  It was 
discovered, upon conducting a literature search, that the anesthetic that was used in this 
study, isoflurane, is capable of influencing the phosphorylation status of GSK3 proteins.  
One study, investigating the effects of anesthetics on global protein phosphorylation in 
adult mouse hippocampi, found that there were 318 significant phosphorylation events 
with respect to 237 different proteins, one of which was GSK3β (Kohtala et al., 2016).  
Another study using a rat model of Parkinson’s Disease (PD) that was investigating the 
effects of brief isoflurane exposure on the phosphorylation of GSK3β, found that there 
were increased levels of Ser9 phosphorylation in both the cortex and the striatum of the 
rats (Leikas et al., 2017).  The effects of the isoflurane must be taken into account when 
designing and conducting experiments due to the confounding effects of its use.  
Appropriate experimental design must include shams for each timepoint analyzed in 
order to better distinguish between the effects of the anesthetic and the effects of the 
treatment.                  
4.3 Characterization of Cellular and Molecular Pathology 
triggered by rmTBI 
In order to validate a clinically relevant model of concussion, rmTBI, we investigated 
whether the closed skin injury delivered by the CCI device generated diffuse axonal 
injury (DAI) using silver stained sections from rmTBI MAPT KI mice.  In terms of the 
short term timepoints investigated (naïve animals, 1 day and 7 day timepoints), and the 
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long term timepoints (4 weeks and 10 weeks), the silver staining showed little positive 
silver staining in the injured groups compared to the shams, which is less than we were 
expecting (Figure 7 and 8).  The variability in the injuries delivered by the CCI device 
can be seen in Figure 9, in which the level of silver staining in injured mice vary from 
very low levels to high levels of silver staining, despite the fact that all animals 
underwent the same injury protocol.  These highly variable results may be explained by 
the fact that the controlled cortical impactor device that I was using throughout the MAPT 
KI study had been malfunctioning, despite being calibrated by myself and others in the 
lab.  Although the outputs that were being read out by the machine itself were the desired 
parameters of the study, it was obvious that the machine was not matching those 
parameters, when the results were being analyzed, and the machine was then sent out to 
be re-calibrated.  Therefore, the rmTBI mice in this study experienced inconsistent 
injuries of variable severity – a fact that must be kept in mind when interpreting the 
results. 
When investigating the pathologically phosphorylated tau, recognized by the AT8 
antibody that recognizes phospho-tau at Ser202/Thr205 (Invitrogen), both 10 week 
injured MAPT KI and C57BL/6 male mice were analyzed.  Images were chosen to 
represent the average amount of staining for each group analyzed.  Pathologically 
phosphorylated tau levels were comparable between the two strains of mice within the 
injured group (Figure 11).  Similarly, both groups of injured mice had increased levels of 
Iba1 reactivity and comparable GFAP reactivity (Figure 13).  Another set of MAPT KI 
and C57BL/6 mice were naturally aged to 12-14 months old.  When analyzing the silver 
staining aged males and females had minimal positive silver staining which was 
comparable between the two strains (Figure 10).  However, when investigating the 
pathologically phosphorylated tau, aged MAPT KI male and female mice had greater 
AT8 staining compared to their C57BL/6 counterparts (Figure 12).  When analyzing the 
staining for the Iba1 and GFAP, there was minimal Iba1 staining and moderate GFAP 
staining for both aged MAPT KI and C57BL/6 animals (Figure 14).     
When this data is considered together, we conclude that the MAPT KI mice should be 
used for rmTBI studies over the C57BL/6 mice due to the observation that just as in aged 
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humans, abnormal tau phosphorylations increase with age in the MAPT KI mice.  This 
observation may be attributed to the tau isoforms expressed in C57BL/6 and the MAPT 
KI mice.  The C57BL/6 mice, do not express any 3R tau isoforms once adulthood is 
reached, with matured neurons expressing solely the 4R tau isoforms (Götz et al., 1995; 
Spillantini & Goedert, 1998).  Adult human brains express all six tau isoforms, where 
both 3R and 4R isoforms are expressed equally at a ratio of approximately 1:1 (M 
Goedert & Jakes, 1990; Hanes et al., 2009).  There are also some sequence differences 
between human and mouse tau that should be taken into consideration due to the fact that 
these sequence differences can have implications for tau function.  For example, the N-
terminal region of human tau contains 11 amino acids that are lacking in mouse tau 
(Hernández et al., 2020).  This variation in the length of the N-terminal region has an 
impact on the potential for tau to form the “paperclip” formation, with the longer human 
tau more likely to form this conformation that its mouse tau counterparts.  The 
“paperclip” conformation involves the folding of the C- and N-terminal ends into the 
microtubule binding repeat domains.  One study combined FRET pair mutants with 
various phospho-mimicking mutations, known to be hyperphosphorylated in AD (AT8, 
PHF1, AT100), in order to investigate the global folding of tau and how the level of 
phosphorylation influences this folding and subsequent conformations (Jeganathan et al., 
2008).  It was determined that the compaction of the paperclip conformation reacted 
positively with the MC1 antibody, an antibody that recognizes pathological 
conformations of tau in the early stages of AD, suggesting that this conformation of tau is 
in fact pathological. 
Improvements in the analysis of both the silver staining and immunohistochemistry could 
be implemented in the future.  In this study, qualitative analysis was conducted, in which 
the sections were visually examined for positive staining.  This approach was used seeing 
as the quantified data would have been variable due to the inconsistent injuries.  
However, using both qualitative and quantitative data would be desirable once the study 
has been repeated.  One could use a computer-assisted image analysis system, similar to 
Williams et al. (2006), in order to calculate the optical density (OD) of the silver staining 
in the sections of interest (Williams et al., 2006).  In terms of the immunohistochemical 
staining, one could use a program such as ImageJ, in order to analyze the photos taken 
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and calculate the percentage of positive staining in the sections of interest (Moszczynski 
et al., 2019).              
4.4 Characterization of the Behavioural Outcomes triggered 
by rmTBI 
The final aim of this study was to characterize the effect of rmTBI on the behaviour of 
MAPT KI mice using the Elevated Plus Maze (EPM) (to test for anxiety/anxiety-like 
behaviours) and the Morris Water Maze (MWM) (to test for spatial learning/memory).  In 
terms of the EPM, injured male MAPT KI mice spent significantly more time in the 
closed arms compared to the shams, although this difference was small; whereas, there 
were no significant differences seen in the behaviours in the female MAPT KI mice 
(Figure 15).  During the Probe Trial of the MWM, there were no significant differences 
in the amount of time spent in the target versus non-target quadrants for both the male 
and female MAPT KI mice (Figure 17), although a trend can be seen for the male and 
female shams to spend more time in the target quadrant.  Unfortunately, during this 
study, COVID-19 interrupted the progression of this work and the numbers of mice in the 
colonies had to be decreased, meaning that we did not have the desired numbers for the 
behavioural studies.  Coupled with the fact that the CCI device was malfunctioning, one 
must not over-analyze these results.  Ideally, these experiments would have been 
replicated with higher n’s and with a fully functioning CCI device.  However, these 
results (the increased anxiety, as seen in the rmTBI males of the EPM, and trends for 
troubled spatial cognition seen in the rmTBI males/females in the MWM), do agree with 
other studies investigating the effects of rmTBI on behaviour post-injury (Broussard et 
al., 2018; W. H. Cheng et al., 2019).  One study testing the hypothesis that rmTBI 
negatively impacts spatial memory and anxiety/anxiety-like behaviours suggested that 
rmTBI does indeed impair spatial memory, as assessed by the MWM, and increases 
anxiety/anxiety-like behaviours, as assessed by the EPM and the Open Field Tests (OFT) 
(Broussard et al., 2018).  Another study utilizing the Closed-Head Impact Model of 
Engineered Rotational Acceleration (CHIMERA) model of rmTBI found that there were 
deficits in the Barnes Maze (BM), another test of spatial learning and memory; however, 
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contrary to this study, there were decreases in anxiety levels in the EPM coinciding with 
increased risk taking behaviour (W. H. Cheng et al., 2019).   
4.5 Caveats of the Novel Mouse Model 
This new mouse model presents potential caveats that should be considered.  First, with 
the humanization of the tau gene, there is concern that the mice do not develop normally 
as they age.  Second, there is the potential for other abnormalities to present themselves 
as the animals age, for example, poor interaction of the human tau with the other mouse 
proteins or accelerated neurodegeneration.  However, there are currently a few papers 
published using these mice that can ease the concerns surrounding these potential 
limitations.  The first study that generated these mice found that neuroinflammation, cell 
death, and overall brain atrophy were not altered or accelerated with the humanization of 
the tau gene in mice aged to 24 months (Hashimoto et al., 2019).  The second paper to 
utilize these mice checked to see if the humanized tau protein was properly integrated 
into the nervous system of the mice.  This study found that the humanized tau protein was 
properly integrated into the nervous system, as it was localized in the axons of the 
neurons, similar to that of the wild type mice (Saito et al, 2019).         
4.6 Conclusions 
The results of this study support the use of MAPT KI mice for rmTBI studies.  
Implications of this study for the future could include applying these results in preclinical 
trials studying the pathophysiological mechanisms activated during recovery from 
rmTBI.  This model could also serve useful for testing inhibitors of GSK3β activity in a 
more clinically relevant model, as human tau is more prone to pathological processes 
compared to wild type mouse tau.  The MAPT KI mice can also be humanized further by 
targeting other genes of interest, such as β-amyloid, and mimicking the protocols used to 
humanize the tau gene.    
4.7 Significance  
Currently, CTE can only be properly diagnosed post-mortem (Turner et al, 2013), which 
is of no use to the individuals whose lives have already been lost.  In order to improve the 
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lives of those affected by neurodegenerative diseases such as CTE, and those of their 
families/loved ones, studies must turn their attention towards the mechanisms and 
pathways that initiate the detrimental cascades, leading to the development of the disease.  
The number of people being affected by repetitive mild traumatic brain injuries is on the 
rise, leading to an increase in the number of individuals developing CTE, additionally, 
causing an increase in the burden/cost to health care systems (Luo et al., 2014).  In order 
to effectively develop a treatment, the time course of pathological activity and 
contributing processes must first be established.  The time of treatment administration 
could then be designed to coincide with the time of peak pathological activity post-injury.  
For example, correctly timed administration of a GSK3β inhibitor might be predicted to 
prevent the abnormal phosphorylation of tau, the formation of tau 
aggregates/fibrils/tangles, and potentially the development of CTE later in life. This work 
is of significant value to both the health and scientific communities since it is one of the 
first, if not the very first, of its kind to explore concussion and tau pathology in a 
clinically relevant model of concussion using transgenic mice solely expressing human 
tau.  This study will hopefully serve as a stepping stone for future preclinical studies of 
rmTBI with a focus on pathophysiology and potential therapeutics.  
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Hryciw, T, Geremia, N, Walker, M, Xu X, Brown A. (2018). Anti-Chondroitin Sulfate 
Proteoglycan Strategies in Spinal Cord Injury: Temporal and Spatial Considerations 
Explain the Balance between Neuroplasticity and Neuroprotection. Journal of 
Neurotrauma. 35(16): 1958-1969. 
 
Thesis/Dissertation 
Mining The Clones: Improving The Phylogenetic Information From A Set Of Clones Of 
Soil-Derived Fungal rNDA. (2018). University of Western Ontario. Bachelor's Honors. 




The Western Scholarship of Excellence                                                            2014-2015 




Freedom 55 Financial Scholar Athlete Award Winner                                    2016-2017 
The University of Western Ontario, London, ON 
 
Dean's Honor List                                                                                               2016-2018 
The University of Western Ontario, London, ON 
 
Dean’s Undergraduate Research Opportunities Program (DUROP)                     2018 
The University of Western Ontario, London, ON 
 
Canada Graduate Scholarships (CGS-M)                                                        2019-2020 




Graduate Teaching Assistant, Biology                                                             2018, 2019                                                                         
The University of Western Ontario, London, ON  
Course Title: 1201A General Biology 1 
Course Level: Undergraduate  
 
Graduate Teaching Assistant, Biology                                                             2018, 2019 
The University of Western Ontario, London, ON  
Course Title: 1001A Biology for Science 1 
Course Level: Undergraduate  
 
Graduate Teaching Assistant, Biology                                                                       2020                                                                         
The University of Western Ontario, London, ON  
Course Title: 1202B General Biology 2 
Course Level: Undergraduate  
 
Graduate Teaching Assistant, Biology                                                                       2020 
The University of Western Ontario, London, ON  
Course Title: 1002B Biology for Science 2 
Course Level: Undergraduate    
 
 
